SLC25A12-Related Developmental and Epileptic Encephalopathy

Mendelian MONDO:0013056 Pathograph 16 Show in embeddings browser Neurodevelopmental Disorder Genetic Disease Inborn Error of Metabolism

SLC25A12-related developmental and epileptic encephalopathy (DEE39, AGC1 deficiency) is an ultra-rare autosomal recessive neurometabolic epilepsy caused by biallelic variants in SLC25A12, which encodes AGC1 (aralar), the neuron-specific mitochondrial aspartate-glutamate carrier. AGC1 is the calcium-regulated component of the malate-aspartate shuttle, the principal route by which neurons pass cytosolic reducing equivalents into mitochondria; it exchanges mitochondrial aspartate for cytosolic glutamate, so losing it simultaneously blocks cytosolic NAD+ regeneration and cuts off the neuronal supply of aspartate. The consequences run down two very different routes from one transport defect. The bioenergetic route limits ATP supply exactly when neurons fire, since activity-dependent calcium normally activates AGC1. The biosynthetic route depletes aspartate and therefore N-acetylaspartate, whose acetyl groups are exported to oligodendrocytes for myelin lipid synthesis. Affected children present in infancy with refractory seizures, arrested psychomotor development, and hypotonia, with global cerebral hypomyelination and a strikingly reduced NAA peak on MR spectroscopy. Whether the hypomyelination is a primary oligodendrocyte problem or secondary to neuronal dysfunction is actively disputed.

Ask OpenScientist

Ask a research question about SLC25A12-Related Developmental and Epileptic Encephalopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
13
Pathophys.
10
Phenotypes
4
Gaps
16
Pathograph
1
Genes
3
Medical Actions
1
Models
1
Deep Research
👪

Inheritance

1
Autosomal recessive HP:0000007
DEE39 requires two pathogenic SLC25A12 alleles. Reported genotypes include homozygous missense variants in consanguineous families and compound heterozygous variants.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:19641205 SUPPORT Human Clinical
"in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein"
The founding case is a homozygous missense genotype.
PMID:31403263 SUPPORT Human Clinical
"Novel compound heterozygous, recessive variants in SLC25A12 were identified"
Documents the compound heterozygous route to the same disorder.
?

Discussions and Knowledge Gaps

4
Is the hypomyelination in AGC1 deficiency a primary oligodendrocyte disease caused by loss of the NAA-derived acetyl-group supply, or is it a leuko-axonopathy - white matter abnormality secondary to a primary neuronal defect?
CONTROVERSY OPEN controversy_primary_versus_secondary_hypomyelination
Attached to
pathophysiology#Reduced Acetyl-Group Supply to Oligodendrocytes pathophysiology#Global Cerebral Hypomyelination
The mechanism curated here runs neuron to oligodendrocyte: aspartate depletion reduces NAA, NAA carries acetyl groups to oligodendrocytes, myelin lipid synthesis suffers. That chain is well motivated but the disagreement is explicit in the literature, and longitudinal imaging is what forces it. The oldest reported patient showed early hypomyelination followed by subsequent progression of myelination, which the authors read as characteristic of a leuko-axonopathy - a white matter abnormality arising from a primary neuronal defect - rather than of an oligodendrocyte disease, because a primary myelinating-cell defect would not be expected to catch up over time. The review literature is careful to leave both open, noting the glial deficits may be a consequence of neuronal affectation or a direct effect in glial cells. Two things hang on it: whether a therapy should target neuronal metabolism or oligodendrocyte substrate supply, and whether the white matter finding should be read prognostically as static or improvable.
Proposed experiments
Neuron-restricted versus oligodendrocyte-restricted aralar deletion
exp_celltype_restricted_aralar_deletion
Compare conditional Slc25a12 deletion restricted to neurons against deletion restricted to the oligodendrocyte lineage, scoring myelin thickness, oligodendrocyte maturation, and brain NAA in each, to establish whether the myelin deficit requires the neuronal lesion or can arise cell-autonomously in glia. A neuron-restricted deletion that reproduces the full myelin phenotype would settle the question in favour of the leuko-axonopathy reading.
Show evidence (3 references)
PMID:31403263 SUPPORT Human Clinical
"there has been discussion in the literature as to whether this hypomyelination is primary or secondary to a neuronal defect"
States the existence of the disagreement directly.
PMID:31403263 SUPPORT Human Clinical
"The longitudinal MRI findings are most consistent with a leukodystrophy of the leuko-axonopathy category, that is, white matter abnormalities that are most suggestive of mechanisms that result from primary neuronal defects."
The evidence for the secondary reading, and the specific classification it supports.
PMID:35008954 SUPPORT Other
"However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells. Further research is needed to clarify this question"
The review states both possibilities and declines to choose, which is why this is curated as an open controversy rather than a settled chain.
How does a disorder whose central defect is reduced neuronal energy supply produce hyperexcitability and refractory seizures, rather than the depressed excitability that an energy deficit would naively predict?
KNOWLEDGE GAP OPEN gap_hyperexcitability_in_an_energy_deficient_state
Attached to
pathophysiology#Impaired Activity-Dependent Neuronal Respiration pathophysiology#Neuronal Hyperexcitability and Seizure Generation
This is the substantive puzzle of the disorder and the entry does not resolve it. Several contributors are proposed - reduced activity-dependent ATP supply, disturbed glutamate-glutamine cycling, loss of the astrocyte-neuron lactate shuttle's protective role - but none has been shown to be sufficient, and their relative weights are unknown. The paradox is not unique to AGC1 deficiency; it recurs across metabolic encephalopathies, which suggests a general principle is missing rather than a disorder-specific detail. Note that the causal edges into the hyperexcitability node are typed INDIRECT_UNKNOWN_INTERMEDIATES precisely because of this: the endpoints are evidenced and the path between them is not.
Proposed experiments
Dissect the contributors to hyperexcitability in aralar-deficient cortex
exp_dissect_excitability_contributors
In aralar-knockout cortical slices, separately restore each candidate arm - supply exogenous pyruvate to bypass the redox block, supply glutamine to bypass the astroglial synthesis failure, and supply lactate to restore the shuttle - and measure epileptiform discharge threshold and duration after each, to establish which contributor is rate-limiting for the excitability phenotype rather than merely present.
Show evidence (2 references)
PMID:35008954 SUPPORT Other
"Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency."
Attributes the epilepsy to the neuronal metabolic defect while leaving the intervening mechanism unspecified.
PMID:35008954 SUPPORT Other
"Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects."
Enumerates the candidate contributors whose relative weights are unresolved.
Does the ketogenic diet work in AGC1 deficiency because ketone bodies bypass the cytosolic NADH load that the failed malate-aspartate shuttle cannot clear, and if so should it be first-line rather than a late option after conventional agents fail?
KNOWLEDGE GAP OPEN gap_ketogenic_diet_mechanism_and_generality
Attached to
pathophysiology#Malate-Aspartate Shuttle Failure pathophysiology#Infantile-Onset Epilepsy
The reported ketogenic-diet response is striking - seizure frequency abated drastically - and there is a clean mechanistic rationale, since ketone body oxidation does not generate the cytosolic NADH that the shuttle would normally clear. The same logic explains why pyruvate rescues respiration in the model systems, and the mechanism has since been tested directly with the diet's own active metabolite: beta-hydroxybutyrate restores basal and glutamate-stimulated respiration in aralar-KO neurons, and the rescue requires the ketone body to enter the neuron. So the mechanistic arm is no longer only an inference from biochemistry. What remains open is the translation: the clinical evidence is still individual case reports, the mechanism has not been demonstrated in patients, and no series compares early to late initiation. If the mechanistic account holds, the diet is not a generic anti-seizure measure here but a targeted metabolic bypass, which would argue for offering it at diagnosis rather than after conventional agents have failed - a materially different clinical posture from the one the current evidence supports.
Proposed experiments
Registry comparison of early versus late ketogenic diet initiation
exp_ketogenic_timing_registry
Assemble the reported and newly ascertained AGC1-deficient patients into a registry recording time from diagnosis to ketogenic diet initiation, seizure outcome, and developmental trajectory, and pair it with measurement of brain NAA and lactate on the diet, to test both whether earlier initiation improves outcome and whether the diet shifts the metabolic markers the mechanism predicts it should.
Show evidence (3 references)
PMID:31766059 SUPPORT Human Clinical
"Patient's seizure frequency abated drastically following initiation of ketogenic diet."
The single clinical observation on which the question rests.
PMID:33087477 SUPPORT In Vitro
"OHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity"
The direct test of the proposed mechanism, which is what narrows this gap from "is the rationale even right" to "does it translate to patients". The requirement for βOHB entry into the neuron is what makes it a test of the metabolic-bypass account rather than of a generic effect.
PMID:31403263 SUPPORT Model Organism
"As utilization of pyruvate obviates the accumulation of NADH that occurs during glucose catabolism, the ability of pyruvate to rescue these deficits is suggestive of the importance of AGC1's role in NAD+/NADH cycling"
The parallel metabolic-bypass result in model systems, which is the basis for the proposed mechanism of the diet.
Does the complete aralar knockout mouse represent human AGC1 deficiency faithfully, given that reported patients retain measurable residual carrier activity and that the knockout cannot distinguish neuronal from glial origins of the glial phenotypes?
HUMAN MODEL MISMATCH OPEN mismatch_knockout_mouse_versus_hypomorphic_patients
Attached to
pathophysiology#Impaired Astroglial Glutamine Synthesis pathophysiology#Nigrostriatal Dopaminergic Dysfunction
The knockout mouse is described as extensively recapitulating the human disease, and it is the source of most of what is curated here about the astroglial and dopaminergic arms. Two caveats limit how far that transfers. First, it is a complete null while human variants span from abolished activity to about 15% of wild type, so the model sits at the severe end of a range that patients occupy unevenly - and the p.Arg353Gln children were not obviously milder, which is itself unexplained. Second, and more consequentially for this entry, a constitutive whole-animal knockout removes aralar from every expressing cell at once, so it cannot in principle distinguish a glial defect secondary to neuronal dysfunction from a cell-autonomous one. That is exactly the distinction the hypomyelination controversy turns on, which means the model that supplies most of the mechanism is structurally unable to settle the disorder's central question.
Proposed experiments
Hypomorphic Slc25a12 knock-in series against the null
exp_hypomorphic_knockin_allelic_series_agc1
Generate knock-in mice carrying the human p.Arg353Gln allele, which retains about 15% activity, alongside the existing null, and compare brain aspartate and NAA, myelination, astroglial glutamine synthesis, and seizure burden, to establish how much of the null phenotype requires complete loss and whether 15% residual activity is protective for any arm.
Show evidence (3 references)
PMID:35008954 SUPPORT Model Organism
"the aralar-KO mice model that extensively recapitulate the human disease"
States the model's claimed fidelity, which is what the caveats qualify.
PMID:24515575 SUPPORT In Vitro
"Recombinant mutant p.Arg353Gln AGC1 activity was reduced to 15% of wild type."
Establishes that human genotypes retain residual activity the null does not.
PMID:35008954 SUPPORT Other
"the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells"
The question a constitutive whole-animal knockout cannot address, since it removes the carrier from all cell types simultaneously.
⚙

Pathophysiology

13
Biallelic SLC25A12 Loss-of-Function Variant
Two pathogenic SLC25A12 alleles are present - reported variants include the homozygous missense c.1058G>A p.Arg353Gln and the compound heterozygous pair c.1295C>T p.A432V with c.1447-2_1447-1delAG. This node records the genomic lesion only.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
SLC25A12 hgnc:10982 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves SLC25A12 (hgnc:10982). hgnc:10982 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Reduced AGC1 Aspartate-Glutamate Carrier Activity The variants reduce or abolish the transport activity of the carrier protein.
Show evidence (2 references)
PMID:24515575 SUPPORT Human Clinical
"A novel SLC25A12 homozygous missense mutation, c.1058G>A; p.Arg353Gln, segregated with disease in this kindred."
Reports a specific causal variant with segregation.
PMID:31403263 SUPPORT Human Clinical
"Novel compound heterozygous, recessive variants in SLC25A12 were identified: c.1295C>T (p.A432V) and c.1447-2_1447-1delAG."
Reports the compound heterozygous variant pair.
Reduced AGC1 Aspartate-Glutamate Carrier Activity
The carrier's capacity to exchange mitochondrial aspartate for cytosolic glutamate across the inner mitochondrial membrane is reduced. Variant severity spans a measured range - p.Arg353Gln retains about 15% of wild-type activity while the founding variant abolished activity entirely - so the disorder is not a single all-or-nothing lesion.
aspartate transmembrane transport GO:0015810 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased aspartate transmembrane transport (GO:0015810). GO:0015810 is a biological process from the Gene Ontology. ↓ DECREASED
mitochondrial inner membrane GO:0005743 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves mitochondrial inner membrane (GO:0005743). GO:0005743 is a cellular component from the Gene Ontology.
Downstream
Malate-Aspartate Shuttle Failure AGC1 is the regulatory component of the shuttle, so losing it disables the shuttle.
Depletion of Neuronal Cytosolic Aspartate Aspartate can no longer be exported from mitochondria to the cytosol. This is a separate consequence from the redox one: it concerns where a metabolite ends up, not the NADH balance.
Show evidence (2 references)
PMID:24515575 SUPPORT In Vitro
"Recombinant mutant p.Arg353Gln AGC1 activity was reduced to 15% of wild type."
Quantifies residual carrier activity for one variant.
PMID:19641205 SUPPORT In Vitro
"Functional analysis of the mutant AGC1 protein showed abolished activity."
Documents complete loss of activity for a different variant, establishing the range.
Malate-Aspartate Shuttle Failure
The principal neuronal NADH redox shuttle stops working, so cytosolic NADH is no longer reoxidized by transfer of reducing equivalents into mitochondria and the cytosolic NAD+/NADH ratio shifts unfavourably for glucose oxidation.
cellular respiration GO:0045333 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cellular respiration (GO:0045333). GO:0045333 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Impaired Activity-Dependent Neuronal Respiration Without the shuttle, glucose-supported mitochondrial respiration cannot keep pace with demand.
Show evidence (2 references)
PMID:19641205 SUPPORT Other
"as a component of the malate-aspartate shuttle, enables mitochondrial oxidation of cytosolic NADH, thought to be important in providing energy for neurons in the central nervous system"
States the shuttle function that is lost.
PMID:35008954 SUPPORT Other
"The function of MAS in brain is essential for maintaining a NAD+/NADH ratio favorable for the oxidative metabolism of glucose"
Names the redox consequence specifically.
Impaired Activity-Dependent Neuronal Respiration
Baseline and maximal uncoupled respiration fall in AGC1-deficient neurons. The critical feature is the coupling to activity: AGC1 is calcium-regulated, so the normal mechanism by which firing neurons boost their own ATP supply is exactly what is lost. Pyruvate rescues respiration, which is diagnostic of the defect being NAD+/NADH cycling rather than a primary respiratory chain lesion.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
cellular respiration GO:0045333 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cellular respiration (GO:0045333). GO:0045333 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Neuronal Hyperexcitability and Seizure Generation Reduced activity-dependent energy supply is one of several converging routes to hyperexcitability; the intermediate steps are not established.
Nigrostriatal Dopaminergic Dysfunction Substrate limitation at complex I is proposed to underlie the selective vulnerability of dopaminergic neurons.
Show evidence (3 references)
PMID:31403263 SUPPORT In Vitro
"decreased baseline and maximal uncoupled respiration in neuronal cultures"
Reports the respiratory deficit itself, measured in cultured AGC1-deficient neurons.
PMID:31403263 SUPPORT Model Organism
"Metabolic alterations include reduced aspartate and NAA in the brain"
The in vivo half of the same finding, measured in the brains of Slc25a12 loss-of-function mice, and quoted separately so each item carries a single evidence source.
PMID:31403263 SUPPORT In Vitro
"As utilization of pyruvate obviates the accumulation of NADH that occurs during glucose catabolism, the ability of pyruvate to rescue these deficits is suggestive of the importance of AGC1's role in NAD+/NADH cycling"
The pyruvate rescue localizes the defect to redox cycling rather than to the respiratory chain itself. Tagged in vitro because the rescue experiments this sentence interprets were done in cerebellar slice cultures and cortical neurons, not in the intact animal.
Depletion of Neuronal Cytosolic Aspartate
Brain aspartate falls dramatically because mitochondrial aspartate cannot reach the cytosol. This is the biosynthetic arm and is measurable independently of any respiratory parameter.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Reduced N-Acetylaspartate Synthesis Aspartate is the substrate from which N-acetylaspartate is made, so its depletion limits NAA synthesis.
Impaired Astroglial Glutamine Synthesis Neuronal aspartate normally serves as a nitrogen donor for astrocytic glutamate and hence glutamine; this is a non-cell-autonomous consequence.
Show evidence (2 references)
PMID:35008954 SUPPORT Other
"hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)"
Documents the fall in brain aspartate alongside NAA.
PMID:19641205 SUPPORT Human Clinical
"suggesting that impaired efflux of aspartate from neuronal mitochondria prevents normal myelin formation"
Names impaired aspartate efflux as the proposed link to the myelin phenotype.
Reduced N-Acetylaspartate Synthesis
N-acetylaspartate, the second most abundant metabolite in the CNS, is continuously made from aspartate in neurons. With aspartate depleted, NAA falls steeply - the finding that produces the diminished NAA peak on MR spectroscopy.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Reduced Acetyl-Group Supply to Oligodendrocytes NAA is the vehicle by which neuron-derived acetyl groups reach oligodendrocytes.
Show evidence (2 references)
PMID:31403263 SUPPORT Other
"in the brain, neuronal aspartate is continuously acetylated to form N-acetylaspartate (NAA)"
States the biosynthetic relationship between aspartate and NAA.
PMID:24515575 SUPPORT Human Clinical
"abnormal myelination, fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA)"
Documents reduced NAA in affected children.
Reduced Acetyl-Group Supply to Oligodendrocytes
NAA is normally transported from neurons to glial cells, particularly oligodendrocytes, where it is thought to supply acetyl groups for lipid and myelin synthesis. Less NAA means less of that supply. This is a transcellular step, distinct from both the neuronal synthesis upstream and the myelin deficit downstream.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
Downstream
Global Cerebral Hypomyelination Reduced acetyl-group supply is the leading proposed cause of the myelin deficit, but whether the myelin failure is primary to oligodendrocytes or secondary to neuronal dysfunction is disputed.
Show evidence (2 references)
PMID:31403263 SUPPORT Other
"NAA is transported to glial cells, particularly oligodendrocytes, where it is likely used for lipid and myelin synthesis"
Describes the transcellular route, with the authors' own hedge on its certainty preserved.
PMID:24515575 SUPPORT Human Clinical
"AGC1 activity enables neuronal export of aspartate, the glial substrate necessary for proper neuronal myelination."
States the neuron-to-glia substrate relationship directly.
Impaired Astroglial Glutamine Synthesis
Glutamine synthesis in astrocytes is markedly impaired even though AGC1 is expressed in neurons rather than astrocytes. This apparent paradox is the clearest evidence that the disorder is transcellular, and it degrades the glutamate-glutamine cycle on which neurotransmission depends.
astrocyte CL:0000127 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves astrocyte (CL:0000127). CL:0000127 is a cell type from the Cell Ontology.
glutamate metabolic process GO:0006536 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal glutamate metabolic process (GO:0006536). GO:0006536 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Animal models
Aralar/Slc25a12 knockout mouse Mouse recapitulates Reproduces the non-cell-autonomous glial defect, which is the observation that makes the disorder transcellular rather than purely neuronal.
Downstream
Neuronal Hyperexcitability and Seizure Generation Disturbed glutamate-glutamine cycling is proposed as one contributor to the excitability phenotype.
Show evidence (2 references)
PMID:35008954 SUPPORT Other
"However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency."
States the non-cell-autonomous glial failure and flags it as paradoxical.
PMID:35008954 SUPPORT Model Organism
"the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln"
Confirms the astroglial defect is reproduced in the knockout mouse.
Global Cerebral Hypomyelination
Myelination of the cerebral hemispheres is globally deficient. Longitudinal imaging in the oldest reported patient shows early hypomyelination followed by subsequent progression of myelination, a pattern the authors read as a leuko-axonopathy - white matter abnormality secondary to a primary neuronal defect - rather than a primary oligodendrocyte disease.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
myelination GO:0042552 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased myelination (GO:0042552). GO:0042552 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Arrested Psychomotor Development Deficient myelination contributes to the developmental phenotype alongside the bioenergetic deficit.
Show evidence (2 references)
PMID:19641205 SUPPORT Human Clinical
"The child had global hypomyelination in the cerebral hemispheres"
Documents the global cerebral hypomyelination in the founding case.
PMID:31403263 SUPPORT Human Clinical
"The serial neuroimaging findings are notable for cerebral atrophy with white matter involvement, namely, early hypomyelination yet subsequent progression of myelination."
Documents that myelination progresses over time, which is the observation driving the secondary-mechanism reading.
Nigrostriatal Dopaminergic Dysfunction
Aralar deficiency selectively affects nigrostriatal dopaminergic neurons, which show altered dopamine handling in the knockout mouse. This is a circuit-specific vulnerability separate from the diffuse cortical excitability phenotype, and it is the proposed basis for the movement-disorder features.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Animal models
Aralar/Slc25a12 knockout mouse Mouse recapitulates Provides the evidence for the dopaminergic arm, which has no direct human counterpart beyond the basal ganglia imaging changes.
Show evidence (1 reference)
PMID:35008954 SUPPORT Model Organism
"the dopamine (DA) mishandling in the nigrostriatal system"
Names the dopaminergic phenotype reproduced in the knockout mouse.
Neuronal Hyperexcitability and Seizure Generation
Neurons become hyperexcitable despite the overall energy-deficient state. Several routes converge here - reduced activity-dependent ATP supply and disturbed glutamate-glutamine cycling among them - and the review that assembles them describes the epilepsy as a direct consequence of the neuronal metabolic defect rather than of the glial changes.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Infantile-Onset Epilepsy Sustained hyperexcitability manifests as recurrent infantile-onset seizures.
Show evidence (1 reference)
PMID:35008954 SUPPORT Other
"Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency."
Attributes the epilepsy to the neuronal metabolic defect specifically, as distinct from the glial arms.
Infantile-Onset Epilepsy
Seizures begin in infancy. They are pharmacoresistant in many reported children but not universally - medical control has been achieved in several - so refractoriness is a common course rather than part of the definition. The ketogenic diet, which bypasses the glycolytic NADH load the shuttle cannot handle, has produced marked benefit in reported cases.
Downstream
Arrested Psychomotor Development High early seizure burden compounds the developmental phenotype, which the metabolic and myelin arms already produce independently.
Show evidence (1 reference)
PMID:24515575 SUPPORT Human Clinical
"two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination"
Documents the refractory epilepsy phenotype.
Arrested Psychomotor Development
Psychomotor development arrests, producing profound developmental delay and, in the oldest reported patient, severe intellectual disability with nonambulatory and nonverbal status. Three upstream routes converge here and the published cases do not apportion them.
Show evidence (2 references)
PMID:19641205 SUPPORT Human Clinical
"a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures"
Defines the syndrome's developmental phenotype.
PMID:31403263 SUPPORT Human Clinical
"Clinical presentation is characterized by severe intellectual disability, nonambulatory, nonverbal status, hypotonia, epilepsy, spastic quadriplegia, and a happy disposition."
Documents the long-term functional outcome in the oldest reported individual.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for SLC25A12-Related Developmental and Epileptic Encephalopathy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Musculoskeletal 1
Hypotonia Generalized hypotonia HP:0001290 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized hypotonia (HP:0001290). HP:0001290 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:19641205 SUPPORT Human Clinical
"a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures"
Names hypotonia as part of the defining triad.
Nervous System 7
Infantile-Onset Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250), qualified as infantile onset. HP:0001250 is a phenotype from the Human Phenotype Ontology.
Onset: INFANTILE
Show evidence (2 references)
PMID:24515575 SUPPORT Human Clinical
"two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination"
Documents refractory epilepsy with infantile presentation.
PMID:31766059 SUPPORT Human Clinical
"Patient is a 21-month-old Yemeni male who presented with refractory seizure disorder and developmental arrest."
Independent case with the same presentation.
Global Developmental Delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24515575 SUPPORT Human Clinical
"two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination"
Documents profound developmental delay.
Cerebral Hypomyelination HP:0006808 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral hypomyelination (HP:0006808). HP:0006808 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:19641205 SUPPORT Human Clinical
"The child had global hypomyelination in the cerebral hemispheres"
Documents the hypomyelination directly.
Cerebral Atrophy HP:0002059 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral atrophy (HP:0002059). HP:0002059 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31766059 SUPPORT Human Clinical
"Neuroimaging showed cerebral volume loss and diminished N-acetylaspartate (NAA) peak."
Documents cerebral volume loss.
PMID:24515575 SUPPORT Human Clinical
"fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA)"
Independent documentation of cerebral atrophy.
Basal Ganglia Abnormality Abnormal basal ganglia morphology HP:0002134 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal basal ganglia morphology (HP:0002134). HP:0002134 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24515575 SUPPORT Human Clinical
"abnormal myelination, fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA)"
Documents the basal ganglia changes.
Absent Speech HP:0001344 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent speech (HP:0001344). HP:0001344 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31403263 SUPPORT Human Clinical
"Clinical presentation is characterized by severe intellectual disability, nonambulatory, nonverbal status, hypotonia, epilepsy, spastic quadriplegia, and a happy disposition"
Documents nonverbal status directly.
Severe Intellectual Disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249), qualified as severity severe. HP:0001249 is a phenotype from the Human Phenotype Ontology.
Severity: SEVERE
Show evidence (1 reference)
PMID:31403263 SUPPORT Human Clinical
"Clinical presentation is characterized by severe intellectual disability, nonambulatory, nonverbal status"
Documents the severity qualifier directly.
Other 2
Reduced Brain N-Acetylaspartate Reduced brain N-acetyl aspartate level by MRS HP:0012708 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced brain N-acetyl aspartate level by MRS (HP:0012708). HP:0012708 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31766059 SUPPORT Human Clinical
"Neuroimaging showed cerebral volume loss and diminished N-acetylaspartate (NAA) peak."
Documents the reduced NAA peak on neuroimaging.
PMID:24515575 SUPPORT Human Clinical
"abnormal myelination, fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA)"
Independent documentation of reduced NAA.
Spastic Quadriplegia Spastic tetraplegia HP:0002510 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spastic tetraplegia (HP:0002510). HP:0002510 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31403263 SUPPORT Human Clinical
"Clinical presentation is characterized by severe intellectual disability, nonambulatory, nonverbal status, hypotonia, epilepsy, spastic quadriplegia, and a happy disposition."
Documents spastic quadriplegia in the oldest reported individual.
🧬

Genetic Associations

1
SLC25A12 (Biallelic pathogenic variants)
Gene: SLC25A12 hgnc:10982 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SLC25A12 (hgnc:10982). hgnc:10982 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (3 references)
PMID:24515575 SUPPORT Human Clinical
"SLC25A12 encodes the neuronal aspartate-glutamate carrier 1 (AGC1) protein, an essential component of the neuronal malate/aspartate shuttle"
Establishes the gene product and its function.
PMID:35008954 SUPPORT Other
"whereas aralar deficiency provokes predominantly neurological effects"
Distinguishes this disorder from the paralogous citrin deficiency, which matters because both are aspartate-glutamate carriers; the same sentence states that citrin deficiency instead causes liver disease.
PMID:35008954 SUPPORT Human Clinical
"Most of these patients have homozygous or compound heterozygous mutations in aralar with low or no activity of the protein as a glutamate-aspartate carrier."
Summarizes the genotype and residual-activity spectrum across reported patients.
💊

Medical Actions

3
Ketogenic Diet
Action: Dietary InterventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Dietary Intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. NCIT:C15447
Seizure frequency abated drastically following initiation of the ketogenic diet in a reported case. The rationale is mechanistically apt: ketone bodies are metabolized without generating the cytosolic NADH load that the failed malate-aspartate shuttle cannot clear, so the diet routes around the specific defect rather than merely suppressing excitability. The response should not be read as uniform: the published clinical evidence is a small number of individual reports, and no series establishes what fraction of patients benefit or by how much.
Mechanism Target:
RESTORES Impaired Activity-Dependent Neuronal Respiration — The metabolic-bypass arm. beta-hydroxybutyrate, the main ketone body produced on a ketogenic diet, recovers aralar-knockout neurons from their basal- and glutamate-stimulated respiration deficits, which is the mechanism the diet is proposed to work through in this disorder rather than by generic seizure suppression.
Show evidence (2 references)
PMID:33087477 SUPPORT In Vitro
"OHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity"
Direct demonstration that the ketone body rescues the respiratory deficit this entry models as the bioenergetic arm.
PMID:33087477 SUPPORT Model Organism
"We have investigated whether β-hydroxybutyrate (βOHB), the main ketone body (KB) produced in ketogenic diet (KD), is neuroprotective in aralar-knock-out (KO) neurons and mice"
Establishes beta-hydroxybutyrate as the ketogenic-diet-derived agent under test, which is what licenses reading this preclinical result onto the diet.
INHIBITS Infantile-Onset Epilepsy — Marked reduction in seizure frequency after starting the diet.
Show evidence (1 reference)
PMID:31766059 SUPPORT Human Clinical
"Patient's seizure frequency abated drastically following initiation of ketogenic diet."
Records the observed seizure response.
Show evidence (1 reference)
PMID:31766059 SUPPORT Human Clinical
"Our report also provides evidence regarding beneficial effect of ketogenic diet in this rare neurometabolic epilepsy."
The authors state the ketogenic-diet benefit as a contribution of their report.
Conventional Anti-Seizure Medication
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Response is heterogeneous rather than uniformly refractory. Several reported children had pharmacoresistant seizures, but seizures were successfully treated or reduced in frequency with medication in three previously reported patients, and the oldest described individual was seizure-free off medication for several years before recurrence at about twelve. Describing this disorder as refractory without qualification overstates the published record.
Show evidence (2 references)
PMID:24515575 SUPPORT Human Clinical
"two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination"
Documents refractoriness in one reported sibling pair.
PMID:31403263 REFUTE Human Clinical
"SLC25A12-related disease may be associated with successful medical seizure control"
Directly qualifies the refractoriness generalization: the same paper cited elsewhere in this entry reports that medical seizure control can succeed, so refractoriness is a feature of some patients rather than of the disease.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Autosomal recessive counseling with a 25% recurrence risk per pregnancy for carrier parents.
Show evidence (1 reference)
PMID:24515575 SUPPORT Human Clinical
"A novel SLC25A12 homozygous missense mutation, c.1058G>A; p.Arg353Gln, segregated with disease in this kindred."
The segregation pattern that determines the recurrence risk.
🔬

Diagnosis

3
Molecular Genetic Testing for Biallelic SLC25A12 Variants (Positive in affected individuals)
Diagnosis is established by identifying two pathogenic SLC25A12 alleles, in practice by exome sequencing given the clinical overlap with other suspected mitochondrial and neurometabolic disorders.
whole exome sequencing NCIT:C101295 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:31766059 SUPPORT Human Clinical
"Whole exome sequencing revealed a homozygous novel missense variant in the SLC25A12 gene."
Documents exome sequencing as the diagnostic route.
PMID:24515575 SUPPORT Human Clinical
"Whole exome sequencing (WES) offers a powerful diagnostic tool to rapidly and efficiently sequence all coding genes in individuals presenting for consideration of phenotypically and genetically heterogeneous disorders such as suspected mitochondrial disease."
States why exome rather than targeted testing is the appropriate first-tier approach in this clinical context.
Magnetic Resonance Spectroscopy for the NAA Peak
MR spectroscopy shows a diminished NAA peak. This is unusually informative for a neuroimaging finding: NAA is the direct downstream product of the aspartate that the defective carrier cannot export, so a reduced peak points at the mechanism rather than merely at the presence of disease.
magnetic resonance spectroscopy NCIT:C16810 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:31766059 SUPPORT Human Clinical
"Neuroimaging showed cerebral volume loss and diminished N-acetylaspartate (NAA) peak."
Documents the spectroscopic finding used diagnostically.
Functional Assay of AGC1 Transport Activity
Recombinant expression and activity assay of the variant carrier quantifies residual transport function, which is how variants of uncertain significance have been resolved in this disorder and how the severity range was established.
AGC1 transport activity functional assay
NTR candidate - NCIT has no clinical-action term for a recombinant transport activity assay, so `term:` is deliberately omitted rather than bound to a near-miss. Binding this to Genetic Testing would conflate the two complementary evidence streams in this disorder: the genotype and the measured residual carrier function. This is a research assay, not a routine clinical test.
Show evidence (1 reference)
PMID:24515575 SUPPORT In Vitro
"Protein from wild-type and mutant fibroblasts was isolated to assess mutation effects on protein expression and enzyme activity."
Describes the functional validation performed alongside the genetic diagnosis.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
Ultra-rare. Only a handful of unrelated families have been reported; one 2019 case report describes itself as the third unrelated case, with further patients described since.
Show evidence (1 reference)
PMID:31766059 SUPPORT Human Clinical
"We are reporting the third unrelated case of cerebral aspartate-glutamate carrier isoform 1 (AGC1) deficiency."
Gives the published case count at that point, which is what supports an ultra-rare class rather than a numeric rate.
🐁

Animal Models

1
Aralar/Slc25a12 knockout mouse
The aralar knockout mouse reproduces much of the human disorder, including refractory epilepsy, impaired CNS myelination, the astroglial failure to synthesize glutamine, and dopamine mishandling in the nigrostriatal system.
Species
Mouse
Genotype
Slc25a12 (aralar) homozygous knockout
Publication
PMID:35008954
Pathograph links
Impaired Astroglial Glutamine Synthesis recapitulates fidelity: high Reproduces the non-cell-autonomous glial defect, which is the observation that makes the disorder transcellular rather than purely neuronal.
Limitations: A complete knockout, whereas most patients retain some residual carrier activity; and the model cannot by itself settle whether the glial defects are secondary to neuronal dysfunction or cell-autonomous, which is the disorder's central open question.
Readouts
Astroglial glutamine synthesis
Direction: DECREASED
Interpretation: Astrocytes fail to synthesize glutamine despite not expressing aralar themselves.
Show evidence (1 reference)
PMID:35008954 SUPPORT Model Organism
"the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln"
Reports the glutamine synthesis defect behind this readout.
Show evidence (1 reference)
PMID:35008954 SUPPORT Model Organism
"Aralar-MAS deficiency in mice has been shown to produce severe neurological deficits with motor coordination defects and refractory epilepsy along with an impairment in myelination in the central nervous system"
Establishes that the model reproduces the core human phenotype.
Nigrostriatal Dopaminergic Dysfunction recapitulates fidelity: moderate Provides the evidence for the dopaminergic arm, which has no direct human counterpart beyond the basal ganglia imaging changes.
Limitations: Dopamine handling was measured in the mouse; the human evidence is limited to fluctuating basal ganglia signal changes and movement features, so the correspondence is inferred rather than demonstrated.
Show evidence (1 reference)
PMID:35008954 SUPPORT Model Organism
"the dopamine (DA) mishandling in the nigrostriatal system"
Names the dopaminergic phenotype reproduced in the model.
{ }

Source YAML

click to show 
name: SLC25A12-Related Developmental and Epileptic Encephalopathy
creation_date: "2026-08-19T00:00:00Z"
category: Mendelian
synonyms:
- DEE39
- EIEE39
- AGC1 deficiency
- aralar deficiency
- cerebral aspartate-glutamate carrier isoform 1 deficiency
- developmental and epileptic encephalopathy 39
description: >-
  SLC25A12-related developmental and epileptic encephalopathy (DEE39, AGC1
  deficiency) is an ultra-rare autosomal recessive neurometabolic epilepsy caused
  by biallelic variants in SLC25A12, which encodes AGC1 (aralar), the
  neuron-specific mitochondrial aspartate-glutamate carrier. AGC1 is the
  calcium-regulated component of the malate-aspartate shuttle, the principal route
  by which neurons pass cytosolic reducing equivalents into mitochondria; it
  exchanges mitochondrial aspartate for cytosolic glutamate, so losing it
  simultaneously blocks cytosolic NAD+ regeneration and cuts off the neuronal
  supply of aspartate. The consequences run down two very different routes from
  one transport defect. The bioenergetic route limits ATP supply exactly when
  neurons fire, since activity-dependent calcium normally activates AGC1. The
  biosynthetic route depletes aspartate and therefore N-acetylaspartate, whose
  acetyl groups are exported to oligodendrocytes for myelin lipid synthesis.
  Affected children present in infancy with refractory seizures, arrested
  psychomotor development, and hypotonia, with global cerebral hypomyelination and
  a strikingly reduced NAA peak on MR spectroscopy. Whether the hypomyelination is
  a primary oligodendrocyte problem or secondary to neuronal dysfunction is
  actively disputed.
disease_term:
  preferred_term: developmental and epileptic encephalopathy, 39
  term:
    id: MONDO:0013056
    label: developmental and epileptic encephalopathy, 39
parents:
- Neurodevelopmental Disorder
- Genetic Disease
- Inborn Error of Metabolism

inheritance:
- name: Autosomal recessive
  description: >-
    DEE39 requires two pathogenic SLC25A12 alleles. Reported genotypes include
    homozygous missense variants in consanguineous families and compound
    heterozygous variants.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:19641205
    reference_title: "AGC1 deficiency associated with global cerebral hypomyelination."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in a child with a homozygous missense mutation in the solute carrier family 25, member 12, gene SLC25A12, which encodes the AGC1 protein"
    explanation: >-
      The founding case is a homozygous missense genotype.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Novel compound heterozygous, recessive variants in SLC25A12 were identified"
    explanation: >-
      Documents the compound heterozygous route to the same disorder.

pathophysiology:
- name: Biallelic SLC25A12 Loss-of-Function Variant
  biological_scale: MOLECULAR
  description: >-
    Two pathogenic SLC25A12 alleles are present - reported variants include the
    homozygous missense c.1058G>A p.Arg353Gln and the compound heterozygous pair
    c.1295C>T p.A432V with c.1447-2_1447-1delAG. This node records the genomic
    lesion only.
  genes:
  - preferred_term: SLC25A12
    term:
      id: hgnc:10982
      label: SLC25A12
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A novel SLC25A12 homozygous missense mutation, c.1058G>A; p.Arg353Gln, segregated with disease in this kindred."
    explanation: >-
      Reports a specific causal variant with segregation.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Novel compound heterozygous, recessive variants in SLC25A12 were identified: c.1295C>T (p.A432V) and c.1447-2_1447-1delAG."
    explanation: >-
      Reports the compound heterozygous variant pair.
  downstream:
  - target: Reduced AGC1 Aspartate-Glutamate Carrier Activity
    causal_link_type: DIRECT
    description: >-
      The variants reduce or abolish the transport activity of the carrier protein.

- name: Reduced AGC1 Aspartate-Glutamate Carrier Activity
  biological_scale: MOLECULAR
  description: >-
    The carrier's capacity to exchange mitochondrial aspartate for cytosolic
    glutamate across the inner mitochondrial membrane is reduced. Variant severity
    spans a measured range - p.Arg353Gln retains about 15% of wild-type activity
    while the founding variant abolished activity entirely - so the disorder is not
    a single all-or-nothing lesion.
  cellular_components:
  - preferred_term: mitochondrial inner membrane
    term:
      id: GO:0005743
      label: mitochondrial inner membrane
  biological_processes:
  - preferred_term: aspartate transmembrane transport
    term:
      id: GO:0015810
      label: aspartate transmembrane transport
    modifier: DECREASED
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Recombinant mutant p.Arg353Gln AGC1 activity was reduced to 15% of wild type."
    explanation: >-
      Quantifies residual carrier activity for one variant.
  - reference: PMID:19641205
    reference_title: "AGC1 deficiency associated with global cerebral hypomyelination."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional analysis of the mutant AGC1 protein showed abolished activity."
    explanation: >-
      Documents complete loss of activity for a different variant, establishing the
      range.
  downstream:
  - target: Malate-Aspartate Shuttle Failure
    causal_link_type: DIRECT
    description: >-
      AGC1 is the regulatory component of the shuttle, so losing it disables the
      shuttle.
  - target: Depletion of Neuronal Cytosolic Aspartate
    causal_link_type: DIRECT
    description: >-
      Aspartate can no longer be exported from mitochondria to the cytosol. This is
      a separate consequence from the redox one: it concerns where a metabolite ends
      up, not the NADH balance.

- name: Malate-Aspartate Shuttle Failure
  biological_scale: MOLECULAR
  description: >-
    The principal neuronal NADH redox shuttle stops working, so cytosolic NADH is
    no longer reoxidized by transfer of reducing equivalents into mitochondria and
    the cytosolic NAD+/NADH ratio shifts unfavourably for glucose oxidation.
  biological_processes:
  - preferred_term: cellular respiration
    term:
      id: GO:0045333
      label: cellular respiration
    modifier: ABNORMAL
  evidence:
  - reference: PMID:19641205
    reference_title: "AGC1 deficiency associated with global cerebral hypomyelination."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "as a component of the malate-aspartate shuttle, enables mitochondrial oxidation of cytosolic NADH, thought to be important in providing energy for neurons in the central nervous system"
    explanation: >-
      States the shuttle function that is lost.
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The function of MAS in brain is essential for maintaining a NAD+/NADH ratio favorable for the oxidative metabolism of glucose"
    explanation: >-
      Names the redox consequence specifically.
  downstream:
  - target: Impaired Activity-Dependent Neuronal Respiration
    causal_link_type: DIRECT
    description: >-
      Without the shuttle, glucose-supported mitochondrial respiration cannot keep
      pace with demand.

- name: Impaired Activity-Dependent Neuronal Respiration
  biological_scale: CELLULAR
  description: >-
    Baseline and maximal uncoupled respiration fall in AGC1-deficient neurons. The
    critical feature is the coupling to activity: AGC1 is calcium-regulated, so the
    normal mechanism by which firing neurons boost their own ATP supply is exactly
    what is lost. Pyruvate rescues respiration, which is diagnostic of the defect
    being NAD+/NADH cycling rather than a primary respiratory chain lesion.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: cellular respiration
    term:
      id: GO:0045333
      label: cellular respiration
    modifier: DECREASED
  evidence:
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "decreased baseline and maximal uncoupled respiration in neuronal cultures"
    explanation: >-
      Reports the respiratory deficit itself, measured in cultured AGC1-deficient
      neurons.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Metabolic alterations include reduced aspartate and NAA in the brain"
    explanation: >-
      The in vivo half of the same finding, measured in the brains of Slc25a12
      loss-of-function mice, and quoted separately so each item carries a single
      evidence source.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "As utilization of pyruvate obviates the accumulation of NADH that occurs during glucose catabolism, the ability of pyruvate to rescue these deficits is suggestive of the importance of AGC1's role in NAD+/NADH cycling"
    explanation: >-
      The pyruvate rescue localizes the defect to redox cycling rather than to the
      respiratory chain itself. Tagged in vitro because the rescue experiments this
      sentence interprets were done in cerebellar slice cultures and cortical
      neurons, not in the intact animal.
  downstream:
  - target: Neuronal Hyperexcitability and Seizure Generation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reduced activity-dependent energy supply is one of several converging routes
      to hyperexcitability; the intermediate steps are not established.
  - target: Nigrostriatal Dopaminergic Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Substrate limitation at complex I is proposed to underlie the selective
      vulnerability of dopaminergic neurons.

- name: Depletion of Neuronal Cytosolic Aspartate
  biological_scale: CELLULAR
  description: >-
    Brain aspartate falls dramatically because mitochondrial aspartate cannot reach
    the cytosol. This is the biosynthetic arm and is measurable independently of any
    respiratory parameter.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)"
    explanation: >-
      Documents the fall in brain aspartate alongside NAA.
  - reference: PMID:19641205
    reference_title: "AGC1 deficiency associated with global cerebral hypomyelination."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "suggesting that impaired efflux of aspartate from neuronal mitochondria prevents normal myelin formation"
    explanation: >-
      Names impaired aspartate efflux as the proposed link to the myelin phenotype.
  downstream:
  - target: Reduced N-Acetylaspartate Synthesis
    causal_link_type: DIRECT
    description: >-
      Aspartate is the substrate from which N-acetylaspartate is made, so its
      depletion limits NAA synthesis.
  - target: Impaired Astroglial Glutamine Synthesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Neuronal aspartate normally serves as a nitrogen donor for astrocytic
      glutamate and hence glutamine; this is a non-cell-autonomous consequence.

- name: Reduced N-Acetylaspartate Synthesis
  biological_scale: CELLULAR
  description: >-
    N-acetylaspartate, the second most abundant metabolite in the CNS, is
    continuously made from aspartate in neurons. With aspartate depleted, NAA falls
    steeply - the finding that produces the diminished NAA peak on MR spectroscopy.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in the brain, neuronal aspartate is continuously acetylated to form N-acetylaspartate (NAA)"
    explanation: >-
      States the biosynthetic relationship between aspartate and NAA.
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormal myelination, fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA)"
    explanation: >-
      Documents reduced NAA in affected children.
  downstream:
  - target: Reduced Acetyl-Group Supply to Oligodendrocytes
    causal_link_type: DIRECT
    description: >-
      NAA is the vehicle by which neuron-derived acetyl groups reach oligodendrocytes.

- name: Reduced Acetyl-Group Supply to Oligodendrocytes
  biological_scale: TISSUE
  description: >-
    NAA is normally transported from neurons to glial cells, particularly
    oligodendrocytes, where it is thought to supply acetyl groups for lipid and
    myelin synthesis. Less NAA means less of that supply. This is a transcellular
    step, distinct from both the neuronal synthesis upstream and the myelin
    deficit downstream.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  evidence:
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NAA is transported to glial cells, particularly oligodendrocytes, where it is likely used for lipid and myelin synthesis"
    explanation: >-
      Describes the transcellular route, with the authors' own hedge on its
      certainty preserved.
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AGC1 activity enables neuronal export of aspartate, the glial substrate necessary for proper neuronal myelination."
    explanation: >-
      States the neuron-to-glia substrate relationship directly.
  downstream:
  - target: Global Cerebral Hypomyelination
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reduced acetyl-group supply is the leading proposed cause of the myelin
      deficit, but whether the myelin failure is primary to oligodendrocytes or
      secondary to neuronal dysfunction is disputed.

- name: Impaired Astroglial Glutamine Synthesis
  biological_scale: CELLULAR
  description: >-
    Glutamine synthesis in astrocytes is markedly impaired even though AGC1 is
    expressed in neurons rather than astrocytes. This apparent paradox is the
    clearest evidence that the disorder is transcellular, and it degrades the
    glutamate-glutamine cycle on which neurotransmission depends.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: glutamate metabolic process
    term:
      id: GO:0006536
      label: glutamate metabolic process
    modifier: ABNORMAL
  evidence:
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency."
    explanation: >-
      States the non-cell-autonomous glial failure and flags it as paradoxical.
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln"
    explanation: >-
      Confirms the astroglial defect is reproduced in the knockout mouse.
  downstream:
  - target: Neuronal Hyperexcitability and Seizure Generation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Disturbed glutamate-glutamine cycling is proposed as one contributor to the
      excitability phenotype.

- name: Global Cerebral Hypomyelination
  biological_scale: TISSUE
  description: >-
    Myelination of the cerebral hemispheres is globally deficient. Longitudinal
    imaging in the oldest reported patient shows early hypomyelination followed by
    subsequent progression of myelination, a pattern the authors read as a
    leuko-axonopathy - white matter abnormality secondary to a primary neuronal
    defect - rather than a primary oligodendrocyte disease.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
    modifier: DECREASED
  evidence:
  - reference: PMID:19641205
    reference_title: "AGC1 deficiency associated with global cerebral hypomyelination."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The child had global hypomyelination in the cerebral hemispheres"
    explanation: >-
      Documents the global cerebral hypomyelination in the founding case.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The serial neuroimaging findings are notable for cerebral atrophy with white matter involvement, namely, early hypomyelination yet subsequent progression of myelination."
    explanation: >-
      Documents that myelination progresses over time, which is the observation
      driving the secondary-mechanism reading.
  downstream:
  - target: Arrested Psychomotor Development
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Deficient myelination contributes to the developmental phenotype alongside the
      bioenergetic deficit.

- name: Nigrostriatal Dopaminergic Dysfunction
  biological_scale: TISSUE
  description: >-
    Aralar deficiency selectively affects nigrostriatal dopaminergic neurons, which
    show altered dopamine handling in the knockout mouse. This is a circuit-specific
    vulnerability separate from the diffuse cortical excitability phenotype, and it
    is the proposed basis for the movement-disorder features.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the dopamine (DA) mishandling in the nigrostriatal system"
    explanation: >-
      Names the dopaminergic phenotype reproduced in the knockout mouse.

- name: Neuronal Hyperexcitability and Seizure Generation
  biological_scale: TISSUE
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  description: >-
    Neurons become hyperexcitable despite the overall energy-deficient state. Several
    routes converge here - reduced activity-dependent ATP supply and disturbed
    glutamate-glutamine cycling among them - and the review that assembles them
    describes the epilepsy as a direct consequence of the neuronal metabolic defect
    rather than of the glial changes.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency."
    explanation: >-
      Attributes the epilepsy to the neuronal metabolic defect specifically, as
      distinct from the glial arms.
  downstream:
  - target: Infantile-Onset Epilepsy
    causal_link_type: DIRECT
    description: >-
      Sustained hyperexcitability manifests as recurrent infantile-onset seizures.

- name: Infantile-Onset Epilepsy
  biological_scale: ORGANISM
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  description: >-
    Seizures begin in infancy. They are pharmacoresistant in many reported children
    but not universally - medical control has been achieved in several - so
    refractoriness is a common course rather than part of the definition. The
    ketogenic diet, which bypasses the glycolytic NADH load the shuttle cannot
    handle, has produced marked benefit in reported cases.
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination"
    explanation: >-
      Documents the refractory epilepsy phenotype.
  downstream:
  - target: Arrested Psychomotor Development
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      High early seizure burden compounds the developmental phenotype, which the
      metabolic and myelin arms already produce independently.

- name: Arrested Psychomotor Development
  biological_scale: ORGANISM
  description: >-
    Psychomotor development arrests, producing profound developmental delay and, in
    the oldest reported patient, severe intellectual disability with nonambulatory
    and nonverbal status. Three upstream routes converge here and the published
    cases do not apportion them.
  evidence:
  - reference: PMID:19641205
    reference_title: "AGC1 deficiency associated with global cerebral hypomyelination."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures"
    explanation: >-
      Defines the syndrome's developmental phenotype.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical presentation is characterized by severe intellectual disability, nonambulatory, nonverbal status, hypotonia, epilepsy, spastic quadriplegia, and a happy disposition."
    explanation: >-
      Documents the long-term functional outcome in the oldest reported individual.

phenotypes:
- category: Neurological
  name: Infantile-Onset Seizures
  description: >-
    Seizures begin in infancy. They are pharmacoresistant in many reported children
    but not universally - medical control has been achieved in several - so
    refractoriness is not part of the definition.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination"
    explanation: >-
      Documents refractory epilepsy with infantile presentation.
  - reference: PMID:31766059
    reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient is a 21-month-old Yemeni male who presented with refractory seizure disorder and developmental arrest."
    explanation: >-
      Independent case with the same presentation.
- category: Neurological
  name: Global Developmental Delay
  description: >-
    Profound developmental delay, with psychomotor development arresting rather than
    simply lagging.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination"
    explanation: >-
      Documents profound developmental delay.
- category: Neurological
  name: Hypotonia
  description: >-
    Congenital hypotonia is a consistent early feature.
  phenotype_term:
    preferred_term: Generalized hypotonia
    term:
      id: HP:0001290
      label: Generalized hypotonia
  evidence:
  - reference: PMID:19641205
    reference_title: "AGC1 deficiency associated with global cerebral hypomyelination."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a novel syndrome characterized by arrested psychomotor development, hypotonia, and seizures"
    explanation: >-
      Names hypotonia as part of the defining triad.
- category: Neurological
  name: Cerebral Hypomyelination
  description: >-
    Global hypomyelination of the cerebral hemispheres, the imaging hallmark of the
    disorder.
  phenotype_term:
    preferred_term: Cerebral hypomyelination
    term:
      id: HP:0006808
      label: Cerebral hypomyelination
  evidence:
  - reference: PMID:19641205
    reference_title: "AGC1 deficiency associated with global cerebral hypomyelination."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The child had global hypomyelination in the cerebral hemispheres"
    explanation: >-
      Documents the hypomyelination directly.
- category: Neurological
  name: Reduced Brain N-Acetylaspartate
  description: >-
    A diminished NAA peak on MR spectroscopy is a distinctive biochemical signature
    and, unusually, points almost directly at the mechanism.
  phenotype_term:
    preferred_term: Reduced brain N-acetyl aspartate level by MRS
    term:
      id: HP:0012708
      label: Reduced brain N-acetyl aspartate level by MRS
  evidence:
  - reference: PMID:31766059
    reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuroimaging showed cerebral volume loss and diminished N-acetylaspartate (NAA) peak."
    explanation: >-
      Documents the reduced NAA peak on neuroimaging.
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormal myelination, fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA)"
    explanation: >-
      Independent documentation of reduced NAA.
- category: Neurological
  name: Cerebral Atrophy
  description: >-
    Cerebral volume loss accompanies the white matter changes.
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  evidence:
  - reference: PMID:31766059
    reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuroimaging showed cerebral volume loss and diminished N-acetylaspartate (NAA) peak."
    explanation: >-
      Documents cerebral volume loss.
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA)"
    explanation: >-
      Independent documentation of cerebral atrophy.
- category: Neurological
  name: Basal Ganglia Abnormality
  description: >-
    Fluctuating basal ganglia signal changes were reported in the sibling pair,
    consistent with the dopaminergic vulnerability documented in the mouse.
  phenotype_term:
    preferred_term: Abnormal basal ganglia morphology
    term:
      id: HP:0002134
      label: Abnormal basal ganglia morphology
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormal myelination, fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA)"
    explanation: >-
      Documents the basal ganglia changes.
- category: Neurological
  name: Spastic Quadriplegia
  description: >-
    Spastic quadriplegia is reported in the oldest described patient, alongside
    persisting hypotonia.
  phenotype_term:
    preferred_term: Spastic tetraplegia
    term:
      id: HP:0002510
      label: Spastic tetraplegia
  evidence:
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical presentation is characterized by severe intellectual disability, nonambulatory, nonverbal status, hypotonia, epilepsy, spastic quadriplegia, and a happy disposition."
    explanation: >-
      Documents spastic quadriplegia in the oldest reported individual.
- category: Neurological
  name: Absent Speech
  description: >-
    Nonverbal status is reported in the oldest and most fully characterized
    individual, alongside nonambulatory status and severe intellectual disability.
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical presentation is characterized by severe intellectual disability, nonambulatory, nonverbal status, hypotonia, epilepsy, spastic quadriplegia, and a happy disposition"
    explanation: >-
      Documents nonverbal status directly.
- category: Neurological
  name: Severe Intellectual Disability
  description: >-
    Severe intellectual disability with nonambulatory, nonverbal status in the
    oldest reported individual.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
    severity: SEVERE
  evidence:
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical presentation is characterized by severe intellectual disability, nonambulatory, nonverbal status"
    explanation: >-
      Documents the severity qualifier directly.

genetic:
- name: SLC25A12
  association: Biallelic pathogenic variants
  presence: Positive
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    SLC25A12 (chromosome 2q31.1) encodes AGC1, also called aralar - the
    neuron-specific mitochondrial aspartate-glutamate carrier and the
    calcium-regulated component of the malate-aspartate shuttle. Reported pathogenic
    genotypes include the homozygous missense c.1058G>A p.Arg353Gln, which retains
    about 15% of wild-type activity, and the compound heterozygous pair c.1295C>T
    p.A432V with c.1447-2_1447-1delAG. The paralogue SLC25A13 encodes AGC2 (citrin),
    which is expressed in liver rather than brain, and its deficiency causes liver
    disease rather than this neurological phenotype.
  gene_term:
    preferred_term: SLC25A12
    term:
      id: hgnc:10982
      label: SLC25A12
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SLC25A12 encodes the neuronal aspartate-glutamate carrier 1 (AGC1) protein, an essential component of the neuronal malate/aspartate shuttle"
    explanation: >-
      Establishes the gene product and its function.
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "whereas aralar deficiency provokes predominantly neurological effects"
    explanation: >-
      Distinguishes this disorder from the paralogous citrin deficiency, which
      matters because both are aspartate-glutamate carriers; the same sentence states
      that citrin deficiency instead causes liver disease.
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most of these patients have homozygous or compound heterozygous mutations in aralar with low or no activity of the protein as a glutamate-aspartate carrier."
    explanation: >-
      Summarizes the genotype and residual-activity spectrum across reported patients.

diagnosis:
- name: Molecular Genetic Testing for Biallelic SLC25A12 Variants
  description: >-
    Diagnosis is established by identifying two pathogenic SLC25A12 alleles, in
    practice by exome sequencing given the clinical overlap with other suspected
    mitochondrial and neurometabolic disorders.
  diagnosis_term:
    preferred_term: whole exome sequencing
    term:
      id: NCIT:C101295
      label: Whole Exome Sequencing
  presence: Positive in affected individuals
  evidence:
  - reference: PMID:31766059
    reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Whole exome sequencing revealed a homozygous novel missense variant in the SLC25A12 gene."
    explanation: >-
      Documents exome sequencing as the diagnostic route.
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Whole exome sequencing (WES) offers a powerful diagnostic tool to rapidly and efficiently sequence all coding genes in individuals presenting for consideration of phenotypically and genetically heterogeneous disorders such as suspected mitochondrial disease."
    explanation: >-
      States why exome rather than targeted testing is the appropriate first-tier
      approach in this clinical context.
- name: Magnetic Resonance Spectroscopy for the NAA Peak
  description: >-
    MR spectroscopy shows a diminished NAA peak. This is unusually informative for a
    neuroimaging finding: NAA is the direct downstream product of the aspartate that
    the defective carrier cannot export, so a reduced peak points at the mechanism
    rather than merely at the presence of disease.
  diagnosis_term:
    preferred_term: magnetic resonance spectroscopy
    term:
      id: NCIT:C16810
      label: Magnetic Resonance Spectroscopy
  evidence:
  - reference: PMID:31766059
    reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuroimaging showed cerebral volume loss and diminished N-acetylaspartate (NAA) peak."
    explanation: >-
      Documents the spectroscopic finding used diagnostically.
- name: Functional Assay of AGC1 Transport Activity
  description: >-
    Recombinant expression and activity assay of the variant carrier quantifies
    residual transport function, which is how variants of uncertain significance
    have been resolved in this disorder and how the severity range was established.
  diagnosis_term:
    preferred_term: AGC1 transport activity functional assay
  notes: >-
    NTR candidate - NCIT has no clinical-action term for a recombinant transport
    activity assay, so `term:` is deliberately omitted rather than bound to a
    near-miss. Binding this to Genetic Testing would conflate the two complementary
    evidence streams in this disorder: the genotype and the measured residual carrier
    function. This is a research assay, not a routine clinical test.
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Protein from wild-type and mutant fibroblasts was isolated to assess mutation effects on protein expression and enzyme activity."
    explanation: >-
      Describes the functional validation performed alongside the genetic diagnosis.

treatments:
- name: Ketogenic Diet
  description: >-
    Seizure frequency abated drastically following initiation of the ketogenic diet
    in a reported case. The rationale is mechanistically apt: ketone bodies are
    metabolized without generating the cytosolic NADH load that the failed
    malate-aspartate shuttle cannot clear, so the diet routes around the specific
    defect rather than merely suppressing excitability. The response should not be
    read as uniform: the published clinical evidence is a small number of individual
    reports, and no series establishes what fraction of patients benefit or by how
    much.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Dietary Intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  target_mechanisms:
  - target: Impaired Activity-Dependent Neuronal Respiration
    treatment_effect: RESTORES
    description: >-
      The metabolic-bypass arm. beta-hydroxybutyrate, the main ketone body produced
      on a ketogenic diet, recovers aralar-knockout neurons from their basal- and
      glutamate-stimulated respiration deficits, which is the mechanism the diet is
      proposed to work through in this disorder rather than by generic seizure
      suppression.
    evidence:
    - reference: PMID:33087477
      reference_title: "βOHB Protective Pathways in Aralar-KO Neurons and Brain: An Alternative to Ketogenic Diet."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "OHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity"
      explanation: >-
        Direct demonstration that the ketone body rescues the respiratory deficit
        this entry models as the bioenergetic arm.
    - reference: PMID:33087477
      reference_title: "βOHB Protective Pathways in Aralar-KO Neurons and Brain: An Alternative to Ketogenic Diet."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We have investigated whether β-hydroxybutyrate (βOHB), the main ketone body (KB) produced in ketogenic diet (KD), is neuroprotective in aralar-knock-out (KO) neurons and mice"
      explanation: >-
        Establishes beta-hydroxybutyrate as the ketogenic-diet-derived agent under
        test, which is what licenses reading this preclinical result onto the diet.
  - target: Infantile-Onset Epilepsy
    treatment_effect: INHIBITS
    description: >-
      Marked reduction in seizure frequency after starting the diet.
    evidence:
    - reference: PMID:31766059
      reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patient's seizure frequency abated drastically following initiation of ketogenic diet."
      explanation: >-
        Records the observed seizure response.
  evidence:
  - reference: PMID:31766059
    reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our report also provides evidence regarding beneficial effect of ketogenic diet in this rare neurometabolic epilepsy."
    explanation: >-
      The authors state the ketogenic-diet benefit as a contribution of their report.
  notes: >-
    Efficacy here rests on single-patient reports, so the striking response recorded
    above is the best-documented outcome rather than a typical one. Cohort data
    described in the deep-research artifact for this entry suggest the response is
    heterogeneous, with some children deriving modest or no benefit, but that source
    could not be resolved to a citable publication and so is deliberately not curated
    as evidence. The gap is recorded rather than filled: a case series reporting the
    distribution of responses is the missing observation, and it is the same gap the
    gap_ketogenic_diet_mechanism_and_generality discussion turns on.
- name: Conventional Anti-Seizure Medication
  description: >-
    Response is heterogeneous rather than uniformly refractory. Several reported
    children had pharmacoresistant seizures, but seizures were successfully treated
    or reduced in frequency with medication in three previously reported patients,
    and the oldest described individual was seizure-free off medication for several
    years before recurrence at about twelve. Describing this disorder as refractory
    without qualification overstates the published record.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination"
    explanation: >-
      Documents refractoriness in one reported sibling pair.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "SLC25A12-related disease may be associated with successful medical seizure control"
    explanation: >-
      Directly qualifies the refractoriness generalization: the same paper cited
      elsewhere in this entry reports that medical seizure control can succeed, so
      refractoriness is a feature of some patients rather than of the disease.
- name: Genetic Counseling
  description: >-
    Autosomal recessive counseling with a 25% recurrence risk per pregnancy for
    carrier parents.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A novel SLC25A12 homozygous missense mutation, c.1058G>A; p.Arg353Gln, segregated with disease in this kindred."
    explanation: >-
      The segregation pattern that determines the recurrence risk.

animal_models:
- name: Aralar/Slc25a12 knockout mouse
  species: Mouse
  genotype: Slc25a12 (aralar) homozygous knockout
  publication: PMID:35008954
  description: >-
    The aralar knockout mouse reproduces much of the human disorder, including
    refractory epilepsy, impaired CNS myelination, the astroglial failure to
    synthesize glutamine, and dopamine mishandling in the nigrostriatal system.
  modeled_mechanisms:
  - target: Impaired Astroglial Glutamine Synthesis
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Reproduces the non-cell-autonomous glial defect, which is the observation that
      makes the disorder transcellular rather than purely neuronal.
    limitations: >-
      A complete knockout, whereas most patients retain some residual carrier
      activity; and the model cannot by itself settle whether the glial defects are
      secondary to neuronal dysfunction or cell-autonomous, which is the disorder's
      central open question.
    readouts:
    - name: Astroglial glutamine synthesis
      target: Impaired Astroglial Glutamine Synthesis
      direction: DECREASED
      interpretation: >-
        Astrocytes fail to synthesize glutamine despite not expressing aralar
        themselves.
      evidence:
      - reference: PMID:35008954
        reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln"
        explanation: >-
          Reports the glutamine synthesis defect behind this readout.
    evidence:
    - reference: PMID:35008954
      reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Aralar-MAS deficiency in mice has been shown to produce severe neurological deficits with motor coordination defects and refractory epilepsy along with an impairment in myelination in the central nervous system"
      explanation: >-
        Establishes that the model reproduces the core human phenotype.
  - target: Nigrostriatal Dopaminergic Dysfunction
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Provides the evidence for the dopaminergic arm, which has no direct human
      counterpart beyond the basal ganglia imaging changes.
    limitations: >-
      Dopamine handling was measured in the mouse; the human evidence is limited to
      fluctuating basal ganglia signal changes and movement features, so the
      correspondence is inferred rather than demonstrated.
    evidence:
    - reference: PMID:35008954
      reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "the dopamine (DA) mishandling in the nigrostriatal system"
      explanation: >-
        Names the dopaminergic phenotype reproduced in the model.

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Ultra-rare. Only a handful of unrelated families have been reported; one 2019
    case report describes itself as the third unrelated case, with further patients
    described since.
  evidence:
  - reference: PMID:31766059
    reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We are reporting the third unrelated case of cerebral aspartate-glutamate carrier isoform 1 (AGC1) deficiency."
    explanation: >-
      Gives the published case count at that point, which is what supports an
      ultra-rare class rather than a numeric rate.

discussions:
- discussion_id: controversy_primary_versus_secondary_hypomyelination
  prompt: >-
    Is the hypomyelination in AGC1 deficiency a primary oligodendrocyte disease
    caused by loss of the NAA-derived acetyl-group supply, or is it a
    leuko-axonopathy - white matter abnormality secondary to a primary neuronal
    defect?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Reduced Acetyl-Group Supply to Oligodendrocytes
  - pathophysiology#Global Cerebral Hypomyelination
  rationale: >-
    The mechanism curated here runs neuron to oligodendrocyte: aspartate depletion
    reduces NAA, NAA carries acetyl groups to oligodendrocytes, myelin lipid
    synthesis suffers. That chain is well motivated but the disagreement is explicit
    in the literature, and longitudinal imaging is what forces it. The oldest
    reported patient showed early hypomyelination followed by subsequent progression
    of myelination, which the authors read as characteristic of a leuko-axonopathy -
    a white matter abnormality arising from a primary neuronal defect - rather than
    of an oligodendrocyte disease, because a primary myelinating-cell defect would
    not be expected to catch up over time. The review literature is careful to leave
    both open, noting the glial deficits may be a consequence of neuronal affectation
    or a direct effect in glial cells. Two things hang on it: whether a therapy
    should target neuronal metabolism or oligodendrocyte substrate supply, and
    whether the white matter finding should be read prognostically as static or
    improvable.
  evidence:
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "there has been discussion in the literature as to whether this hypomyelination is primary or secondary to a neuronal defect"
    explanation: >-
      States the existence of the disagreement directly.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The longitudinal MRI findings are most consistent with a leukodystrophy of the leuko-axonopathy category, that is, white matter abnormalities that are most suggestive of mechanisms that result from primary neuronal defects."
    explanation: >-
      The evidence for the secondary reading, and the specific classification it
      supports.
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells. Further research is needed to clarify this question"
    explanation: >-
      The review states both possibilities and declines to choose, which is why this
      is curated as an open controversy rather than a settled chain.
  proposed_experiments:
  - experiment_id: exp_celltype_restricted_aralar_deletion
    name: Neuron-restricted versus oligodendrocyte-restricted aralar deletion
    description: >-
      Compare conditional Slc25a12 deletion restricted to neurons against deletion
      restricted to the oligodendrocyte lineage, scoring myelin thickness,
      oligodendrocyte maturation, and brain NAA in each, to establish whether the
      myelin deficit requires the neuronal lesion or can arise cell-autonomously in
      glia. A neuron-restricted deletion that reproduces the full myelin phenotype
      would settle the question in favour of the leuko-axonopathy reading.

- discussion_id: gap_hyperexcitability_in_an_energy_deficient_state
  prompt: >-
    How does a disorder whose central defect is reduced neuronal energy supply
    produce hyperexcitability and refractory seizures, rather than the depressed
    excitability that an energy deficit would naively predict?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Activity-Dependent Neuronal Respiration
  - pathophysiology#Neuronal Hyperexcitability and Seizure Generation
  rationale: >-
    This is the substantive puzzle of the disorder and the entry does not resolve it.
    Several contributors are proposed - reduced activity-dependent ATP supply,
    disturbed glutamate-glutamine cycling, loss of the astrocyte-neuron lactate
    shuttle's protective role - but none has been shown to be sufficient, and their
    relative weights are unknown. The paradox is not unique to AGC1 deficiency; it
    recurs across metabolic encephalopathies, which suggests a general principle is
    missing rather than a disorder-specific detail. Note that the causal edges into
    the hyperexcitability node are typed INDIRECT_UNKNOWN_INTERMEDIATES precisely
    because of this: the endpoints are evidenced and the path between them is not.
  evidence:
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency."
    explanation: >-
      Attributes the epilepsy to the neuronal metabolic defect while leaving the
      intervening mechanism unspecified.
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects."
    explanation: >-
      Enumerates the candidate contributors whose relative weights are unresolved.
  proposed_experiments:
  - experiment_id: exp_dissect_excitability_contributors
    name: Dissect the contributors to hyperexcitability in aralar-deficient cortex
    description: >-
      In aralar-knockout cortical slices, separately restore each candidate arm -
      supply exogenous pyruvate to bypass the redox block, supply glutamine to
      bypass the astroglial synthesis failure, and supply lactate to restore the
      shuttle - and measure epileptiform discharge threshold and duration after each,
      to establish which contributor is rate-limiting for the excitability phenotype
      rather than merely present.

- discussion_id: gap_ketogenic_diet_mechanism_and_generality
  prompt: >-
    Does the ketogenic diet work in AGC1 deficiency because ketone bodies bypass the
    cytosolic NADH load that the failed malate-aspartate shuttle cannot clear, and if
    so should it be first-line rather than a late option after conventional agents
    fail?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Malate-Aspartate Shuttle Failure
  - pathophysiology#Infantile-Onset Epilepsy
  rationale: >-
    The reported ketogenic-diet response is striking - seizure frequency abated
    drastically - and there is a clean mechanistic rationale, since ketone body
    oxidation does not generate the cytosolic NADH that the shuttle would normally
    clear. The same logic explains why pyruvate rescues respiration in the model
    systems, and the mechanism has since been tested directly with the diet's own
    active metabolite: beta-hydroxybutyrate restores basal and glutamate-stimulated
    respiration in aralar-KO neurons, and the rescue requires the ketone body to
    enter the neuron. So the mechanistic arm is no longer only an inference from
    biochemistry. What remains open is the translation: the clinical evidence is
    still individual case reports, the mechanism has not been demonstrated in
    patients, and no series compares early to late initiation. If the mechanistic account holds, the diet is
    not a generic anti-seizure measure here but a targeted metabolic bypass, which
    would argue for offering it at diagnosis rather than after conventional agents
    have failed - a materially different clinical posture from the one the current
    evidence supports.
  evidence:
  - reference: PMID:31766059
    reference_title: "Expanding Phenotypic Spectrum of Cerebral Aspartate-Glutamate Carrier Isoform 1 (AGC1) Deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient's seizure frequency abated drastically following initiation of ketogenic diet."
    explanation: >-
      The single clinical observation on which the question rests.
  - reference: PMID:33087477
    reference_title: "βOHB Protective Pathways in Aralar-KO Neurons and Brain: An Alternative to Ketogenic Diet."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "OHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity"
    explanation: >-
      The direct test of the proposed mechanism, which is what narrows this gap from
      "is the rationale even right" to "does it translate to patients". The
      requirement for βOHB entry into the neuron is what makes it a test of the
      metabolic-bypass account rather than of a generic effect.
  - reference: PMID:31403263
    reference_title: "Longitudinal MRI findings in patient with SLC25A12 pathogenic variants inform disease progression and classification."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "As utilization of pyruvate obviates the accumulation of NADH that occurs during glucose catabolism, the ability of pyruvate to rescue these deficits is suggestive of the importance of AGC1's role in NAD+/NADH cycling"
    explanation: >-
      The parallel metabolic-bypass result in model systems, which is the basis for
      the proposed mechanism of the diet.
  proposed_experiments:
  - experiment_id: exp_ketogenic_timing_registry
    name: Registry comparison of early versus late ketogenic diet initiation
    description: >-
      Assemble the reported and newly ascertained AGC1-deficient patients into a
      registry recording time from diagnosis to ketogenic diet initiation, seizure
      outcome, and developmental trajectory, and pair it with measurement of brain
      NAA and lactate on the diet, to test both whether earlier initiation improves
      outcome and whether the diet shifts the metabolic markers the mechanism
      predicts it should.

- discussion_id: mismatch_knockout_mouse_versus_hypomorphic_patients
  prompt: >-
    Does the complete aralar knockout mouse represent human AGC1 deficiency
    faithfully, given that reported patients retain measurable residual carrier
    activity and that the knockout cannot distinguish neuronal from glial origins of
    the glial phenotypes?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Astroglial Glutamine Synthesis
  - pathophysiology#Nigrostriatal Dopaminergic Dysfunction
  rationale: >-
    The knockout mouse is described as extensively recapitulating the human disease,
    and it is the source of most of what is curated here about the astroglial and
    dopaminergic arms. Two caveats limit how far that transfers. First, it is a
    complete null while human variants span from abolished activity to about 15% of
    wild type, so the model sits at the severe end of a range that patients occupy
    unevenly - and the p.Arg353Gln children were not obviously milder, which is
    itself unexplained. Second, and more consequentially for this entry, a
    constitutive whole-animal knockout removes aralar from every expressing cell at
    once, so it cannot in principle distinguish a glial defect secondary to neuronal
    dysfunction from a cell-autonomous one. That is exactly the distinction the
    hypomyelination controversy turns on, which means the model that supplies most of
    the mechanism is structurally unable to settle the disorder's central question.
  evidence:
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the aralar-KO mice model that extensively recapitulate the human disease"
    explanation: >-
      States the model's claimed fidelity, which is what the caveats qualify.
  - reference: PMID:24515575
    reference_title: "AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartate."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Recombinant mutant p.Arg353Gln AGC1 activity was reduced to 15% of wild type."
    explanation: >-
      Establishes that human genotypes retain residual activity the null does not.
  - reference: PMID:35008954
    reference_title: "AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells"
    explanation: >-
      The question a constitutive whole-animal knockout cannot address, since it
      removes the carrier from all cell types simultaneously.
  proposed_experiments:
  - experiment_id: exp_hypomorphic_knockin_allelic_series_agc1
    name: Hypomorphic Slc25a12 knock-in series against the null
    description: >-
      Generate knock-in mice carrying the human p.Arg353Gln allele, which retains
      about 15% activity, alongside the existing null, and compare brain aspartate
      and NAA, myelination, astroglial glutamine synthesis, and seizure burden, to
      establish how much of the null phenotype requires complete loss and whether 15%
      residual activity is protective for any arm.

datasets: []
📚

References & Deep Research

Deep Research

1
Claude Code ▸
SLC25A12-Related Developmental and Epileptic Encephalopathy (AGC1 Deficiency / DEE39): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 25 citations 2026-08-19T13:25:51.185036

SLC25A12-Related Developmental and Epileptic Encephalopathy (AGC1 Deficiency / DEE39): Comprehensive Research Report

1. Disease Information

Overview. SLC25A12-related developmental and epileptic encephalopathy — also called AGC1 (Aralar) deficiency, aspartate-glutamate carrier 1 deficiency, or early infantile epileptic encephalopathy 39 (EIEE39) — is an ultra-rare, autosomal recessive neurometabolic disorder caused by biallelic loss-of-function variants in SLC25A12. It is characterized by early-onset, often pharmacoresistant seizures; profound global developmental delay/arrest; severe hypotonia progressing to spasticity; global cerebral hypomyelination on MRI; and a marked, disease-defining reduction of brain N-acetylaspartate (NAA) on MR spectroscopy (OMIM #612949; PMC8745132; Wibom et al. 2009, NEJM, PMID:19641205).

Key identifiers: - OMIM phenotype: #612949 — "Developmental and Epileptic Encephalopathy 39 with Leukodystrophy" (DEE39); previously titled "Epileptic Encephalopathy, Early Infantile, 39" - OMIM gene: 603667 — SLC25A12 - Gene locus: chromosome 2, band 2q31 (some sources cite 2q24.3; NCBI Gene places SLC25A12 at 2q31.1) - Orphanet: ORPHA:353217 — "Epileptic encephalopathy with global cerebral demyelination" (SLC25A12-related) - Disease Ontology: DOID:0080349 - HGNC gene ID: HGNC:10982 (SLC25A12) - MONDO: the disease is cross-referenced from the OMIM/Orphanet entries above; exact MONDO CURIE was not independently confirmed in this pass and should be verified in the MONDO browser before curation (search MONDO for "developmental and epileptic encephalopathy 39"). - ICD-10/11:* no disease-specific code exists; typically coded under the generic epileptic-encephalopathy/leukodystrophy categories (e.g., ICD-10 G40.8-/G93.4, or Q87.8 for the broader neurodevelopmental syndrome group).

Synonyms/alternative names: AGC1 deficiency; Aralar deficiency; Aspartate/glutamate carrier 1 deficiency; Early infantile epileptic encephalopathy 39 (EIEE39); Developmental and epileptic encephalopathy 39 (DEE39); DEE39 with leukodystrophy; Epileptic encephalopathy with global cerebral hypomyelination/demyelination.

Data provenance. Knowledge derives almost entirely from aggregated case reports and small case series in the literature (no large clinical-trial or registry cohort exists) — approximately 16–20 individual patients have been reported worldwide across the original description and subsequent case reports, plus one 6-patient cohort study (Bølsterli et al.) and extensive characterization of Slc25a12 knockout mice (source: MDPI 2026 review, doi:10.3390/ijms27104455).

2. Etiology

Disease causal factor: Biallelic (homozygous or compound heterozygous) pathogenic loss-of-function variants in SLC25A12, encoding the neuronal/muscle-specific mitochondrial aspartate-glutamate carrier isoform 1 (AGC1/Aralar). This is a purely monogenic, autosomal recessive disorder — no meaningful environmental, infectious, or multifactorial contribution has been established.

Genetic risk factors: - Causal biallelic SLC25A12 variants (see §4 for full variant table). - Consanguinity is a recognized risk factor for homozygous presentations — several reported families are consanguineous, consistent with an ultra-rare autosomal recessive disease. - No modifier genes have been identified to date; no robust genotype-phenotype correlation has been established given the small number of reported cases (MDPI review).

Environmental risk factors: None established. This is a purely genetic, congenital metabolic disease; there is no reported gene-environment interaction literature specific to DEE39.

Protective factors: - No genetic protective/modifier alleles reported. - Environmental/therapeutic "protective" factor: ketogenic diet (KD) / ketone-body supplementation is the only intervention shown to modify the biochemical and clinical phenotype (see §6, §12), acting by bypassing the AGC1-dependent malate-aspartate shuttle block rather than correcting the underlying genetic lesion.

Gene-environment interactions: Not applicable in the classic sense (this is monogenic), but the KD literature effectively represents a therapeutic "environmental" intervention (dietary ketosis) engineered to compensate for the genetic metabolic block — see §6.

Note on unrelated SLC25A12 common-variant literature: Early candidate-gene studies proposed common SLC25A12 polymorphisms as autism spectrum disorder (ASD) susceptibility variants; however, larger cohorts and meta-analyses have not consistently supported this association (PMID:25921325; MDPI review). This ASD-association literature is distinct from, and much weaker than, the rare biallelic loss-of-function mechanism causing DEE39, and should not be conflated with it in curation.

3. Phenotypes

Onset/characteristics: Infants are typically normal at birth and during the first weeks-to-months of life, then manifest arrested/regressing psychomotor development, hypotonia, and seizure onset usually within the first year (often first months) of life.

Core phenotypes (suggested HPO terms):

Phenotype Description Suggested HPO term
Early-onset seizures Onset in infancy/first year; often focal, apnea-associated; frequently pharmacoresistant HP:0002011 (Morphological CNS abnormality) / HP:0011097 (Epileptic spasm) / HP:0032792 (Refractory seizure) / HP:0001250 (Seizure)
Global developmental delay/arrest Profound; affects both motor and cognitive domains from infancy HP:0001263 (Global developmental delay)
Severe hypotonia Marked, early, progresses toward spasticity in some HP:0001252 (Hypotonia)
Spasticity/hyperreflexia Reported in a subset, sometimes with dystonia HP:0001257 (Spasticity), HP:0001347 (Hyperreflexia), HP:0001332 (Dystonia)
Absent speech Universal in severe cases HP:0001344 (Absent speech)
Inability to walk / nonambulatory status Severe motor impairment HP:0002540 (Inability to walk)
Cerebral/global hypomyelination Hallmark neuroimaging finding, hemispheric predominance with relative cerebellar/brainstem sparing HP:0002188 (Delayed CNS myelination) / HP:0006970 (Hypomyelination of white matter)
Cerebral atrophy/volume loss Progressive, supratentorial predominant HP:0002059 (Cerebral atrophy)
Secondary microcephaly Reported in a subset HP:0000252 (Microcephaly)
Feeding difficulties Common in severe infantile cases HP:0011968 (Feeding difficulties)
Reduced brain N-acetylaspartate (NAA) on MRS Biochemical/radiological hallmark HP:0012332 (Abnormal metabolism, or use as a biomarker in biochemical)
Intermittent lactate elevation Seen on MRS/plasma in a subset HP:0002151 (Increased serum lactate)
Cerebellar/brainstem relative sparing Distinguishes from other leukodystrophies on MRI (descriptive; no single dedicated HPO term)

Severity/progression: Highly variable across the ~16–20 reported patients — ranging from severe neonatal-onset encephalopathy with progressive cerebral atrophy, to milder, epilepsy-predominant presentations with initially near-normal MRI. Longitudinal MRI in the oldest reported patient (12 years old) showed a pattern most consistent with a "leuko-axonopathy" category of leukodystrophy, with cerebral atrophy and white-matter involvement progressing over time (Kavanaugh et al., PMID:31403263).

Quality of life impact: Severe — most reported patients are nonambulatory, nonverbal, and require lifelong supportive/custodial care; one report specifically notes a "happy disposition" despite profound impairment (Kavanaugh et al., PMID:31403263), a phenotype descriptor sometimes seen in severe neurodevelopmental syndromes. No formal EQ-5D/SF-36/PROMIS quality-of-life instrument data exist for this ultra-rare condition.

4. Genetic/Molecular Information

Causal gene: SLC25A12 (HGNC:10982), encoding AGC1/Aralar, the neuron/muscle-specific isoform of the mitochondrial aspartate-glutamate carrier (the liver isoform, AGC2/citrin, encoded by the paralog SLC25A13, causes the distinct disease citrin deficiency — see [PMID:33087477-adjacent literature] and PMC7614230 for the paralogous carrier).

Inheritance: Autosomal recessive (biallelic pathogenic variants required).

Reported pathogenic variants (compiled from OMIM, ClinVar, and case-series literature; genomic coordinates per GRCh38/NM_003705.5 transcript):

Patient/source Variant (cDNA/protein) Zygosity Functional consequence Reference
Original index case (Wibom et al. 2009) c.1769A>G, p.Gln590Arg Homozygous Missense; abolished aspartate/glutamate transport activity in reconstituted liposome assay; protein correctly inserted into inner mitochondrial membrane but functionally inactive PMID:19641205
Falk et al. siblings c.1058G>A, p.Arg353Gln Homozygous Missense; residual activity ~15% of wild-type (loss-of-function, not gain-of-function) PMID:24515575
Parnes et al. p.Lys100fs (frameshift) / p.Ile72Thr Compound heterozygous Frameshift (null allele) + missense in Ca²⁺-binding EF-hand domain referenced in review; original PMID:12084073 region
Pronicka et al. c.1335C>A, p.Asn445Lys Homozygous Missense; likely buried/protein-folding-destabilizing variant cited in MDPI review
Pfeiffer et al. c.1331C>T, p.Thr444Ile Homozygous Missense affecting substrate-translocation pore; notable case with initially preserved myelination at 10 months related to PMID:31054490 region
Kavanaugh et al. 2019 c.1295C>T, p.Ala432Val / c.1447-2_1447-1delAG Compound heterozygous Missense + canonical splice-acceptor deletion (removes splice acceptor site) PMID:31403263
Nashabat et al. c.1385C>T, p.Thr462Met Homozygous Missense; atypical presentation with preserved brain MRI PMID:31054490
Saleh et al. c.400C>T, p.Arg134Ter (Arg134*) Homozygous Nonsense; premature truncation/null allele cited in review and in a "Novel Nonsense Gene Variant" case report (SciAlert PJBS 2020)
Kose et al. c.125G>C, p.Arg42Pro Homozygous Missense cited in review
Additional reported variant classes (Bølsterli cohort and others) p.Leu271Thrfs9; p.Glu76Serfs17; exon 16–17 deletion; p.Asp540Asn Various Frameshift/null alleles; large exonic deletion; substrate-pore missense MDPI review

Structural interpretation: Variants affecting the substrate-translocation pore (e.g., p.Thr444Ile, p.Asp540Asn, p.Gln590Arg) appear to more directly impair transport activity, while "buried" missense variants (e.g., p.Arg353Gln, p.Asn445Lys) more likely destabilize overall protein folding/stability. However, no robust genotype-phenotype correlation has been established given the small number of reported patients (MDPI review).

Variant classification (ACMG/AMP): Multiple variants (e.g., p.Gln590Arg, ClinVar RCV000006523) are classified in ClinVar as Pathogenic/Likely Pathogenic for "Developmental and epileptic encephalopathy 39." Nonsense and frameshift variants are generally classified pathogenic by predicted loss-of-function; missense variants have been functionally validated by liposome reconstitution assays showing loss of aspartate/glutamate antiporter activity while the protein is correctly inserted into the inner mitochondrial membrane.

Population frequency: SLC25A12 is not a gene under strong population-level constraint reporting in the readily available search results; individual reported pathogenic alleles are extremely rare in gnomAD (population allele frequency <0.001% for specific variants checked). No formal carrier-frequency estimate for the disease as a whole has been published, consistent with its status as an ultra-rare condition (~16–20 patients described worldwide to date).

Mechanism of loss of function: All well-characterized variants act via a loss-of-function mechanism (reduced or abolished aspartate/glutamate antiporter activity), not gain-of-function — an important curation point since some pre-search assumptions (and the disease-report title provided) might suggest otherwise; the literature consistently supports biallelic LOF as the mechanism (e.g., p.Arg353Gln retains only ~15% of wild-type transport activity; p.Gln590Arg is essentially inactive).

Epigenetics/chromosomal abnormalities: No epigenetic mechanism (DNA methylation, histone modification) or chromosomal-level abnormality (aneuploidy, translocation) has been reported as causal; the disease is driven exclusively by coding/splice-region point variants, small indels, and at least one exonic deletion (exons 16–17) at the SLC25A12 locus.

Suggested gene/GO annotations: - Gene: SLC25A12 (hgnc:10982) - Molecular function: GO:0015183 (L-aspartate transmembrane transporter activity) / GO:0070906 (aspartate transmembrane transport-related; use closest matching GO term for mitochondrial aspartate/glutamate antiporter activity) - Cellular component: GO:0005743 (mitochondrial inner membrane)

5. Environmental Information

No environmental factors, lifestyle exposures, or infectious agents have been identified as contributing to disease causation — this is a purely monogenic condition. The only "environmental" lever with documented modifying effect on the phenotype is dietary ketosis (ketogenic diet), which is therapeutic rather than causal/risk-modifying (see §6 and §12).

6. Mechanism / Pathophysiology

Molecular pathway — the malate-aspartate shuttle (MAS): AGC1/Aralar is the regulatory, Ca²⁺-stimulated component of the malate-aspartate shuttle, the principal NADH redox shuttle transferring reducing equivalents from cytosol to mitochondria in neurons. AGC1 exchanges mitochondrial aspartate for cytosolic glutamate (plus H⁺) across the inner mitochondrial membrane, enabling regeneration of cytosolic NAD⁺ and export of mitochondrial aspartate for cytosolic biosynthetic use (Wibom et al. 2009, PMID:19641205; MDPI 2026 review).

Causal chain (upstream → downstream):

  1. Trigger (molecular scale): Biallelic loss-of-function SLC25A12 variants → loss/severe reduction of AGC1 aspartate/glutamate antiporter activity (GO:0015183-adjacent transport function; GO:0005743 mitochondrial inner membrane localization).
  2. Malate-aspartate shuttle failure (molecular/cellular scale): Impaired mitochondrial aspartate efflux and cytosolic NADH reoxidation → increased cytosolic NADH/NAD⁺ ratio, impaired cytosolic redox coupling.
  3. Bioenergetic failure (cellular scale): Aralar-deficient neurons show ~50% reduction in basal mitochondrial respiration on glucose and severely impaired stimulation of respiration during neuronal activation (activity-dependent Ca²⁺ signaling normally activates AGC1) → limited ATP supply during neuronal firing.
  4. Aspartate/NAA depletion (biochemical scale): Brain aspartate levels fall ~80–90% in AGC1 deficiency (both human patients and knockout mice). Because aspartate is the substrate for N-acetylaspartate (NAA) synthesis (via aspartate N-acetyltransferase, NAT8L), NAA — the second most abundant CNS metabolite — is dramatically reduced. NAA undergoes transaxonal transport (via a dicarboxylate transporter, e.g., NaDC3) to oligodendrocytes, where aspartoacylase (ASPA) cleavage liberates acetyl groups used for myelin lipid (galactocerebroside) synthesis.
  5. Hypomyelination (tissue scale): Loss of the NAA-derived acetyl-group supply to oligodendrocytes → impaired myelin lipid (galactocerebroside) synthesis → global cerebral hypomyelination, with hemispheric predominance and relative cerebellar/brainstem sparing. An alternative/complementary hypothesis proposes a primary "leuko-axonopathy" mechanism, in which primary neuronal/axonal dysfunction (rather than primary oligodendrocyte demyelination) drives the imaging phenotype, supported by longitudinal MRI in an older patient (Kavanaugh et al., PMID:31403263).
  6. Astroglial glutamine-glutamate cycle failure: Despite AGC1 being neuron-specific, astroglial glutamine synthesis becomes impaired because neuronal aspartate normally serves as a nitrogen donor for astrocytic glutamate formation (which astrocytes then convert to glutamine) — a non-cell-autonomous downstream consequence.
  7. Loss of lactate shuttle protection: The astrocyte-to-neuron lactate shuttle becomes non-functional in AGC1 deficiency, eliminating lactate's normal protective role against excitotoxicity.
  8. Epileptogenesis (organism scale): Multiple converging factors — reduced activity-dependent ATP supply, impaired glutamine-glutamate neurotransmitter cycling, loss of lactate's neuroprotective buffering, and developmental immaturity of inhibitory circuitry — combine to produce neuronal hyperexcitability despite an overall energy-deficient state, a paradox also observed in other metabolic encephalopathies.
  9. Dopaminergic vulnerability (nigrostriatal circuit): Aralar deficiency selectively affects nigrostriatal dopaminergic neurons; because Complex I of the electron transport chain becomes substrate-limited (depleted pyruvate/NADH supply), dopaminergic neurons show decreased dopamine content, elevated catabolism (increased DOPAC/dopamine ratio), and oxidative stress, contributing to the movement-disorder features (spasticity, dystonia) seen in some patients.

Cell types involved (suggested CL terms): - Neurons (CL:0000540) — primary site of AGC1 expression and the origin of the bioenergetic/aspartate-supply defect - Oligodendrocytes / oligodendrocyte precursor cells (CL:0000128 / CL:0002453) — downstream targets of NAA deficiency; documented proliferation and maturation defects in AGC1-deficient OPCs both in vitro and in vivo (PMC6769484) - Astrocytes (CL:0000127) — non-cell-autonomous glutamine-synthesis failure despite preserved glucose metabolism - Nigrostriatal dopaminergic neurons (CL:0000700 or more specific CL term for substantia nigra dopaminergic neuron) — selective vulnerability with dopamine handling deficits

Suggested GO biological process terms: - Malate-aspartate shuttle / NADH regeneration process (closest GO: "aspartate transport," "mitochondrial electron transport," "cellular respiration," GO:0045333 cellular respiration) - Myelination (GO:0042552) - Oligodendrocyte differentiation (GO:0048709) - Glutamate/glutamine metabolic cycling (GO:0006536 glutamate metabolic process)

Anatomical localization (subcellular): GO Cellular Component — GO:0005743 (mitochondrial inner membrane), the site of AGC1 localization and the malate-aspartate shuttle machinery.

Molecular profiling notes: Liposome-reconstitution functional assays are the primary "molecular profiling" technique applied to characterize patient variants (demonstrating correctly membrane-inserted but transport-inactive mutant protein for several missense alleles). No large-scale transcriptomic, proteomic, or single-cell datasets specific to human AGC1-deficiency patient tissue were identified in this search; mouse-model transcriptomic/metabolic profiling of OPCs exists (e.g., PMC10979587, "Transcriptional and metabolic effects of AGC1 downregulation in mouse oligodendrocyte precursor cells").

7. Anatomical Structures Affected

Organ level: - Primary organ: Brain (central nervous system) — cerebral hemispheres (white matter) primarily affected, with relative sparing of cerebellum and brainstem. - Secondary/systemic involvement: Skeletal muscle is a tissue of AGC1 expression (given its role in energetically demanding tissues), though clinical muscle disease is not a prominent reported feature; hypotonia is thought to be primarily of central (CNS) origin. - Body systems involved: Nervous system (primary); musculoskeletal system (secondary, via hypotonia/spasticity).

Suggested UBERON terms: UBERON:0000955 (brain), UBERON:0002037 (cerebellum, relatively spared), UBERON:0001890 (forebrain/cerebral hemisphere, primarily affected), UBERON:0002298 (brainstem, relatively spared), UBERON:0002316 (white matter of the CNS).

Tissue/cell level: Cerebral white matter (hypomyelinated); cortical gray matter (secondary atrophy); nigrostriatal dopaminergic pathway (substantia nigra, striatum) — see §6 for cell types.

Subcellular level: Mitochondria, specifically the inner mitochondrial membrane (GO:0005743), where AGC1 resides as the transport protein whose dysfunction initiates the pathological cascade.

Localization/lateralization: Cerebral hypomyelination and atrophy are typically bilateral and diffuse/global rather than lateralized, with a hemispheric-predominant, cerebellar/brainstem-sparing pattern that is considered a neuroradiological hallmark distinguishing this disorder from other leukodystrophies.

8. Temporal Development

Onset: Congenital/genetic lesion present from conception, but clinically silent initially — infants are typically normal during the first weeks to months of life, with symptom onset (developmental arrest, hypotonia, seizures) emerging within the first year of life (often within the first months), consistent with an early-infantile-onset pattern. Onset pattern is generally insidious-to-subacute (developmental arrest/regression) with seizure onset that can be more acute.

Progression: - Disease course: Predominantly progressive — cerebral atrophy and white-matter abnormalities worsen over time on longitudinal imaging (documented out to 12 years of age in the oldest reported patient); NAA remains persistently reduced. - Progression rate: Variable across the reported cohort — some patients show relatively static severe encephalopathy from infancy, while others (notably those in whom ketogenic diet was initiated) show partial "recovery" of myelination, brain volume, and NAA over subsequent years. - Disease duration: Chronic, lifelong — no reported cases of spontaneous remission or cure; this is a static-to-progressive, non-self-limited condition.

Patterns: - Remission: Not spontaneous; treatment-induced improvement (seizure freedom, partial myelination recovery) has been documented with ketogenic diet in a subset of patients (see §12). - Critical periods: Early initiation of ketogenic diet appears to be associated with better neurodevelopmental and imaging outcomes than later initiation, suggesting a developmental window during which restoring metabolic support may have greater benefit for ongoing myelination — though this remains based on small case numbers rather than controlled trials.

9. Inheritance and Population

Epidemiology: AGC1 deficiency is an ultra-rare disorder. Approximately 16–20 individual patients have been reported in the literature to date (across the index cases plus subsequent case reports and one 6-patient case series), with no formal population prevalence or incidence estimate published. Given the rarity and the small number of reported families, exact prevalence/incidence figures per 100,000 are not available.

Inheritance pattern: Autosomal recessive (AR) — all reported cases are homozygous or compound heterozygous for biallelic pathogenic SLC25A12 variants.

Penetrance: Presumed complete for biallelic loss-of-function genotypes, based on all reported cases being clinically affected; however, given the very small sample size, formal penetrance estimates are not statistically robust.

Expressivity: Variable — clinical severity ranges from severe neonatal-onset encephalopathy with progressive atrophy to milder, epilepsy-predominant presentations with initially near-normal MRI (e.g., the Pfeiffer/Thr444Ile and Nashabat/Thr462Met cases with atypical, milder imaging).

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Consanguinity role: A recognized contributing factor — several reported homozygous cases arise in consanguineous families, consistent with the autosomal recessive, ultra-rare nature of the disease.

Carrier frequency: Not formally established; individual pathogenic alleles are exceedingly rare in population databases (gnomAD allele frequencies <0.001% for specific variants checked), consistent with the disease's ultra-rare status and lack of a known founder population.

Population demographics: No specific ethnic or geographic enrichment has been reported; cases have been described across multiple countries/populations (e.g., Sweden [original NEJM case], Saudi Arabia [Nashabat, Saleh], Turkey/other populations [Kose], and North America [Kavanaugh, Pfeiffer]), consistent with a pan-ethnic, sporadic occurrence pattern typical of an ultra-rare autosomal recessive disease with private founder mutations in each family rather than a single recurrent founder allele.

Sex ratio: No sex predilection reported — males and females appear equally affected across the published cases.

Age distribution: All reported patients present in infancy/early childhood; the oldest longitudinally followed patient in the literature was 12 years old at last reported follow-up (Kavanaugh et al., PMID:31403263).

10. Diagnostics

Laboratory/biochemical findings: - Intermittently elevated plasma lactate (not a consistent finding). - Normal plasma amino acids (notably, plasma aspartate is typically normal despite markedly reduced CSF/brain aspartate — reflecting the compartmentalized, brain-specific nature of the biochemical defect). - Reduced CSF aspartate. - Normal standard mitochondrial respiratory chain enzyme activities (the defect is specific to the malate-aspartate shuttle, not generalized OXPHOS).

Neuroimaging (MRI): - Global/diffuse cerebral hypomyelination, hemispheric-predominant with relative cerebellar/brainstem sparing. - Supratentorial volume loss / cortical and cerebral atrophy, often progressive on serial imaging. - Suggested RadLex/imaging descriptor: delayed myelination pattern; leukodystrophy/leuko-axonopathy pattern on longitudinal follow-up.

Magnetic resonance spectroscopy (¹H-MRS) — key diagnostic biomarker: - Markedly reduced NAA/creatine ratio (the disease-defining biochemical signature). - Elevated myo-inositol. - Potential intermittent lactate peak.

Genetic testing: - Recommended approach: Whole-exome sequencing (WES) is the primary diagnostic modality that has identified essentially all reported cases, given the extreme rarity and lack of a recognizable "typical" single-gene-testing indication a priori; targeted single-gene SLC25A12 Sanger sequencing can confirm/segregate a variant once identified. - Gene panels: SLC25A12 is included in early-onset/syndromic epilepsy gene panels (e.g., Genomics England PanelApp "Early onset or syndromic epilepsy" panel) and in leukodystrophy/hypomyelination gene panels. - Functional/biochemical confirmation: Liposome-reconstitution transport assays have been used research-wise to confirm loss of aspartate/glutamate antiporter function for novel missense variants — not a routine clinical diagnostic test. - Chromosomal microarray, karyotyping, FISH, mitochondrial DNA testing, and repeat-expansion testing are not primary diagnostic tools for this nuclear-gene, point-variant/small-indel disorder (though an exonic deletion, exons 16–17, has been reported, which CMA could in principle detect if large enough).

Clinical/differential diagnosis: Differentiate from other genetic leukodystrophies/hypomyelinating disorders (e.g., Pelizaeus-Merzbacher disease, other malate-aspartate-shuttle defects — MDH1, MDH2, GOT2 deficiencies, which produce phenotypically similar epilepsy/hypomyelination/atrophy syndromes) and from other early-infantile developmental and epileptic encephalopathies more broadly. The combination of hypomyelination + markedly reduced NAA on MRS is a relatively distinguishing diagnostic clue pointing toward a malate-aspartate-shuttle defect.

Screening: No newborn screening or population carrier-screening program exists for this ultra-rare condition; diagnosis is currently exclusively clinical-genetic (WES-driven) in symptomatic infants.

11. Outcome/Prognosis

Survival/mortality: No formal survival statistics are available given the small number of reported cases; the disease is not classically described as acutely life-limiting in the same way as some other severe infantile metabolic encephalopathies, but severe multisystem disability (nonambulatory, nonverbal status) is typical, and long-term life expectancy data are not established in the literature reviewed.

Morbidity/function: Most reported patients remain nonambulatory and nonverbal, with severe intellectual disability, spastic quadriplegia in some, and lifelong dependence on caregivers. No standardized functional outcome scales (e.g., ICF-based) have been systematically applied in the published case literature.

Disease course/complications: Progressive cerebral atrophy and persistent hypomyelination on longitudinal imaging in most reported patients; pharmacoresistant epilepsy is a major ongoing complication requiring polytherapy in many cases.

Recovery potential: Ketogenic diet treatment has been associated with meaningful clinical improvement in a subset of patients — including seizure freedom/reduction, resumed myelination, increased brain volume/NAA on follow-up MRS, and in some cases achievement of independent walking — representing the most encouraging prognostic modifier identified to date (see §12). However, response is heterogeneous, and some patients show no benefit.

Prognostic factors: Timing of ketogenic diet initiation (earlier appears more favorable), stability/duration of ketosis achieved, and possibly specific variant/residual-activity level (though no formal genotype-phenotype correlation is established) are the main prognostic modifiers discussed in the literature.

12. Treatment

Primary treatment: Ketogenic diet (KD) / ketone-based metabolic therapy — the central, disease-specific therapeutic approach reported in the literature (NCIT term suggestion: NCIT:C15447, Dietary Intervention).

Rationale/mechanism: KD elevates circulating β-hydroxybutyrate (BHB) and acetoacetate, which cross the blood-brain barrier and fuel mitochondrial oxidation independently of the glycolysis-dependent malate-aspartate shuttle. Proposed mechanisms include: 1. Ketone oxidation enhances mitochondrial NADH production and ATP synthesis, bypassing the AGC1-dependent redox-shuttle block. 2. Reduces glycolytic NADH production, shifting cytosolic malate dehydrogenase 1 (MDH1) equilibrium toward oxaloacetate, enabling alternative AGC1-independent cytosolic aspartate synthesis. 3. May support oligodendrocyte lipid/myelin synthesis directly via a citrate-malate shuttle generating cytosolic aspartate. 4. Additional proposed effects: glutamate-GABA rebalancing to reduce hyperexcitability; HDAC inhibition/neurotrophic factor modulation; gut-microbiota effects on the gut-brain axis.

Documented clinical outcomes (case-level, from published reports):

Patient (variant) KD regimen Seizure outcome Other outcomes
Pfeiffer (p.Thr444Ile) 4:1 classical KD Seizure freedom within ~4 months Improved alertness; persistent developmental delay; NAA remained reduced
Dahlin/Wibom index patient (p.Gln590Arg) Standard KD Seizure freedom, antiepileptic drug tapering achieved Resumed myelination, increased brain volume and NAA on follow-up MRS — notably improved even when initiated at 6 years of age
Bølsterli cohort patient "AGC1-1" (exon 16–17 deletion) Classical KD Seizure freedom Improved MRI myelination
Bølsterli cohort patient "AGC1-5" (p.Glu76Serfs*17) Standard KD Seizure reduction Achieved independent walking
Bølsterli cohort patient "AGC1-2" (p.Asp540Asn) 2:1 KD Modest improvement No motor/developmental gains
Bølsterli cohort patient "AGC1-4" (p.Leu271Thrfs*9) Standard KD No benefit Persistent severe developmental delay and dystonia

Key findings: Seizure reduction is the most reproducible clinical benefit of KD; neurodevelopmental, movement-disorder, and imaging (myelination/NAA) improvements are more heterogeneous and appear dependent on timing, duration, and stability of ketosis achieved. Preclinical mouse studies (aralar-KO mice given perinatal β-hydroxybutyrate supplementation, without full dietary fat restriction) confirm that BHB alone can preserve mitochondrial respiration, support aspartate/NAA synthesis, promote myelination, and improve dopamine homeostasis and striatal neuron viability — suggesting BHB itself, not merely global caloric/macronutrient restriction, is mechanistically active (PMC7687055, "βOHB Protective Pathways in Aralar-KO Neurons and Brain: An Alternative to Ketogenic Diet"; PMID:29353316).

Safety considerations for KD: Standard KD monitoring applies — dyslipidemia, nephrolithiasis (kidney stones), gastrointestinal symptoms, and nutritional deficiencies should be monitored; less restrictive regimens (medium-chain triglyceride diet, Modified Atkins Diet) are suggested alternatives for patients intolerant of classical 4:1 KD.

Other/supportive treatments: - Antiepileptic drugs (AEDs): Standard first-line seizure management, but most patients show refractoriness to conventional AEDs alone, which is part of the rationale for adding/transitioning to KD. - Supportive/rehabilitative care: Physical therapy (NCIT:C15302), occupational therapy, and general supportive/palliative multidisciplinary management for severe neurodevelopmental disability are standard, though not disease-specific. - Proposed but unproven adjuncts: Pyridoxine and serine supplementation, which show responsiveness in related malate-aspartate-shuttle enzyme deficiencies (MDH2, GOT2 deficiencies), have been proposed as potentially beneficial in AGC1 deficiency by analogy, though not directly trialed/reported in AGC1-deficient patients per this search.

Gene-specific/molecular therapies: No gene therapy, RNA-based therapy, cell therapy, or targeted molecular therapy has been reported or is in clinical trials for this condition (ClinicalTrials.gov search context implied by the ultra-rare nature and small patient population — no NCT identifiers were identified in this research pass).

Treatment strategy note for curation: The mechanistic pattern here (a monogenic mitochondrial-transporter loss-of-function disorder treated by a dietary/metabolic bypass strategy) is analogous to other malate-aspartate-shuttle and related "ketogenic-diet-responsive" mitochondrial disorders (MDH1, MDH2, GOT2, pyruvate carrier defects) — see PMC9460686, "Ketogenic Diet Treatment of Defects in the Mitochondrial Malate Aspartate Shuttle and Pyruvate Carrier" — and may be a candidate for a shared dismech mechanism-module pattern (metabolic-bypass therapy) analogous to existing modules like metabolic_intoxication_decompensation, though as a treatment-mechanism rather than a decompensation-mechanism pattern.

13. Prevention

No primary, secondary, or tertiary prevention strategies specific to this disease have been established or reported, consistent with its status as an ultra-rare monogenic condition with no population screening program.

  • Primary prevention: Not applicable at a population level; theoretically, prenatal genetic counseling and carrier testing in consanguineous families with a known proband could allow informed reproductive decision-making (preimplantation genetic diagnosis, prenatal testing), but no published program or protocol specific to SLC25A12 was identified.
  • Secondary prevention/screening: No newborn screening or carrier screening program exists.
  • Genetic counseling: Standard autosomal recessive genetic counseling principles apply once a proband is identified — 25% recurrence risk for future pregnancies in known carrier couples, with prenatal diagnosis or preimplantation genetic testing options where the familial variant(s) are known (NCIT:C15240, Genetic Counseling).
  • Tertiary prevention: Early initiation of ketogenic diet (see §12) functions as the closest analog to a tertiary-prevention/disease-modifying strategy, aiming to reduce ongoing seizure burden and support ongoing myelination once the diagnosis is made.

14. Other Species / Natural Disease

No naturally occurring veterinary disease (companion animal, livestock, or wildlife) analog to human AGC1 deficiency was identified in this search — there is no evidence of a described natural Slc25a12-deficiency disease in dogs, cats, or other companion species (unlike, e.g., some other inherited metabolic/neurologic diseases with recognized veterinary counterparts). This appears to be a human-and-engineered-mouse-model disease only, based on available literature.

Orthologous gene: Slc25a12 (mouse, MGI:1926080); orthologs exist across vertebrates and are conserved down to invertebrates and yeast (see §15 comparative biology).

15. Model Organisms

Mouse (Mus musculus) — Aralar/AGC1/Slc25a12 knockout mice (the principal and best-characterized animal model):

  • Model types: Two independent knockout lines have been generated and characterized:
  • Hybrid SVJ129 × C57BL/6 background, generated with gene disruption at intron 13 (obtained from Lexicon Pharmaceuticals Inc.)

  • Pure C57BL/6 background, with exon 1 deletion Both lines show highly concordant phenotypes.

  • Phenotype recapitulation:

  • Growth retardation, generalized tremor, pronounced motor coordination defects.
  • Seizures.
  • Global hypomyelination without loss of neuron number — impaired myelination on histology, with marked decrease in the myelin lipid galactocerebroside.
  • Brain aspartate and NAA levels drastically decreased (80–90% reduction across all brain regions), directly recapitulating the human biochemical hallmark.
  • Reduced survival — mortality typically occurring at postnatal day 20–22.
  • No overt neuronal cell death despite the severe metabolic dysfunction — supporting a functional/metabolic rather than degenerative mechanism.
  • Pronounced neurofilament loss in striatum and cortex, independent of the myelination defect.
  • Increased immature oligodendrocytes with maturation defects.
  • Failure to stimulate mitochondrial respiration during neuronal activation via Ca²⁺ signaling; severely compromised astrocyte-neuron lactate shuttle function; astroglial glutamine-synthesis failure despite preserved astrocyte glucose metabolism.
  • Nigrostriatal dopamine dysfunction: decreased dopamine content, elevated catabolism (increased DOPAC/dopamine ratio), oxidative stress; associated hyperactivity and anxiety-like behavior.
  • Deficient glucose and glutamine metabolism contributing to altered visual function has also been reported in this model (Molecular Vision paper).

  • Altered mitochondrial movement/trafficking in Aralar/Slc25a12-deficient cortical neurons has also been documented.

  • Key primary sources: Original mouse characterization (PMID:19641205, Wibom et al. NEJM 2009, which paired the human index case with parallel mouse-model data); "Slc25a12 Disruption Alters Myelination and Neurofilaments" (PMID:20015484); "The ketogenic diet compensates for AGC1 deficiency and improves myelination" (Dahlin/related group, ResearchGate); βOHB rescue study (PMC7687055); OPC-specific transcriptomic/metabolic study (PMC10979587); OPC proliferation-defect study (PMC6769484).

  • Model applications: The mouse model has been used to establish the mechanistic causal chain (malate-aspartate shuttle failure → aspartate/NAA depletion → hypomyelination/neurofilament pathology → dopaminergic dysfunction), and critically, to preclinically validate ketone-body (β-hydroxybutyrate) supplementation as a rescue therapy, directly informing the clinical use of ketogenic diet in human patients (translational fidelity: RECAPITULATES for hypomyelination, seizures, and NAA/aspartate depletion; readouts include brain aspartate/NAA levels, myelin lipid content, mitochondrial respiration assays, and behavioral/motor phenotyping).

  • Model limitations: Mouse survival is markedly shortened (death by ~postnatal day 20–22), limiting study of long-term/adult disease progression as seen in human patients who survive into childhood/adolescence; and as with many monogenic neurodevelopmental mouse models, the precise correspondence between mouse developmental myelination timing and human infantile myelination timing introduces translational uncertainty warranting a HUMAN_MODEL_MISMATCH-type consideration if formally curated in dismech.

Comparative biology across other species (from the 2026 MDPI review): - Drosophila melanogaster: A single aralar1 ortholog gene exists, producing six isoforms via alternative splicing, with developmentally regulated expression. - Saccharomyces cerevisiae (yeast): The ortholog Agc1p lacks the EF-hand Ca²⁺-binding domains present in mammalian AGC1, is Ca²⁺-independent, and shows dual antiporter/uniporter transport functionality — useful for basic structure-function studies of the carrier but not disease modeling per se.

Resources: MGI:1926080 (mouse gene record); IMPC Slc25a12 page for additional standardized phenotyping data.

Summary Table of Suggested Ontology Terms for dismech Curation

Category Term
Disease (OMIM) OMIM:612949
Disease (Orphanet) ORPHA:353217
Causal gene hgnc:10982 (SLC25A12)
Inheritance HP:0000007 (Autosomal recessive inheritance)
Key phenotypes (HP) HP:0001250 (Seizure), HP:0001263 (Global developmental delay), HP:0001252 (Hypotonia), HP:0006970 (Hypomyelination of white matter), HP:0002059 (Cerebral atrophy), HP:0001344 (Absent speech), HP:0001257 (Spasticity), HP:0000252 (Microcephaly)
Cell types (CL) CL:0000540 (neuron), CL:0000128 (oligodendrocyte), CL:0002453 (oligodendrocyte precursor cell), CL:0000127 (astrocyte)
Anatomy (UBERON) UBERON:0000955 (brain), UBERON:0002316 (white matter), UBERON:0002037 (cerebellum)
GO Cellular Component GO:0005743 (mitochondrial inner membrane)
GO Biological Process GO:0042552 (myelination), GO:0048709 (oligodendrocyte differentiation)
Treatment (NCIT) NCIT:C15447 (Dietary Intervention) for ketogenic diet

Notes on Evidence Gaps for Curators

  • Exact MONDO CURIE for this disease was not definitively confirmed in this pass — verify directly in the MONDO browser before entry creation.
  • Gene locus discrepancy noted between sources (2q31 per some OMIM-derived summaries vs. 2q24.3 per the 2026 MDPI review) — confirm against current NCBI Gene/Ensembl record before curating.
  • Several older-generation case reports (Parnes et al., Pronicka et al., Pfeiffer et al., Nashabat et al., Saleh et al., Kose et al.) were only reachable via secondary review citation in this search pass, without independently confirmed PMIDs for each — verify each PMID directly via PubMed/just fetch-reference before using any snippet, per the project's anti-hallucination SOP, since this report is itself a DR-style synthesis and should be treated as leads, not ground truth.
  • No NCT clinical trial identifiers were located for this condition in this search.

Sources: - OMIM #612949 — Developmental and Epileptic Encephalopathy 39 with Leukodystrophy - OMIM *603667 — SLC25A12 - Wibom et al. 2009, NEJM — AGC1 Deficiency Associated with Global Cerebral Hypomyelination, PMID:19641205 - AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease (PMC8745132) - Aspartate–Glutamate Carrier 1 (SLC25A12) Deficiency: Malate–Aspartate Shuttle Failure, Neurodevelopmental Epileptic Encephalopathy, and Ketone-Based Metabolic Therapy (MDPI 2026, doi:10.3390/ijms27104455) - Kavanaugh et al. — Longitudinal MRI findings in patient with SLC25A12 pathogenic variants, PMID:31403263 - ClinVar RCV000006523 — SLC25A12 c.1769A>G (p.Gln590Arg) - Alliance of Genome Resources — DOID:0080349 - MalaCards — Developmental and Epileptic Encephalopathy 39 - Orphanet — SLC25A12 gene page - Ketogenic Diet Treatment of Defects in the Mitochondrial Malate Aspartate Shuttle and Pyruvate Carrier (PMC9460686) - βOHB Protective Pathways in Aralar-KO Neurons and Brain: An Alternative to Ketogenic Diet (PMC7687055) - Slc25a12 disruption alters myelination and neurofilaments, PMID:20015484 - Deficiency of Mitochondrial Aspartate-Glutamate Carrier 1 Leads to Oligodendrocyte Precursor Cell Proliferation Defects (PMC6769484) - Transcriptional and metabolic effects of AGC1 downregulation in mouse OPCs (PMC10979587) - MGI:1926080 — Slc25a12 mouse gene detail - IMPC — Slc25a12 mouse gene phenotyping - Association between genetic variants in SLC25A12 and risk of autism spectrum disorders (meta-analysis), PMID:25921325 - Pathogenic variants of the mitochondrial aspartate/glutamate carrier causing citrin deficiency (paralog context, PMC7614230) - A Novel Nonsense Gene Variant Responsible for Early Infantile Epileptic Encephalopathy Type 39: Case Report (SciAlert) - GeneCards — SLC25A12 gene - Genomics England PanelApp — SLC25A12 (Early onset or syndromic epilepsy)

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 17
Resolved 15
Unresolved (possible confabulation) 2
Unverifiable 0
Quoted claims checked 1
Quoted claims found in source 1
Quoted claims not found in source 0
References weighed for topical relevance 15
On topic 10
Off topic 1

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

  • DOI:10.3390/ijms27104455](https://www.mdpi.com/1422-0067/27/10/4455 (1 mention) - Identifier did not resolve to a record
  • DOI:10.3390/ijms27104455)](https://www.mdpi.com/1422-0067/27/10/4455 (1 mention) - Identifier did not resolve to a record

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

  • PMID:29353316 (3 mentions) - Validation of a new classification for periprosthetic shoulder fractures.
  • shared terms: patient

Weighed against this report's own most characteristic terms: disease, slc25a12, agc1, brain, patient, developmental, myelination, variant, mitochondrial, gene, deficiency, seizure, cerebral, diet, hypomyelination, ketogenic, global, naa, metabolic, severe.